"country","lat","diagnosis","study_no","url","pubMedId","registry_ID","site_name","enrolment","pub_year","drugs","pub_title","region","lon","status","authors","other_drugs","t_design","multiRegional","diagnosticMethod","hiv_co_infection","disease","otherCountries"
India (IND),25.612677,,"265",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371363/,28355259,CTRI/2016/05/006958,"Rajendra Memorial Research Institute of Medical Sciences, Patna, India",50,2017,Amphotericin B - formulation unknown,To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). ,India Subcontinent,85.158875,Published,"Vidya Nand Rabi Das, Nyamat Ali Siddiqui, Biplab Pal, Chandra Shekhar Lal, Neena Verma, Ashish Kumar, Rakesh Bihari Verma, Dhirendra Kumar, Pradeep Das, Krishna Pandey  ","",RCT,0,Mixed,No,pkdl,
India (IND),25.613897,Spleen/bone,"67",http://www.ncbi.nlm.nih.gov/pubmed/21036835,21036834,-9,"Balaji Uthan Sansthan, Patna, India",230,2010,Amphotericin B deoxycholate,Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.,India Subcontinent,85.139591,Published,"Thakur CP, Kumar A, Mitra DK, Roy A, Sinha AK, Ranjan A.",Amphotericin B,Comparative,0,Parasitological,No,vl,
Bangladesh (BGD),24.742748,Serological,"82",http://www.ncbi.nlm.nih.gov/pubmed/21734128,21734127,-9,"Mymensingh District, Bangladesh",977,2011,Miltefosine,Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.,India Subcontinent,90.408589,Published,"Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B.",Miltefosine,Single Group,0,Serological,No,vl,
India (IND),25.464987,Spleen/bone,"155",http://www.ncbi.nlm.nih.gov/pubmed/9251374,9251373,-9,"IOC Hospital, Barauni, India",54,1996,Roxithromycin,Experience with roxithromycin in visceral leishmaniasis in north Bihar.,India Subcontinent,85.988148,Published,"Lal SK, Lal R, Lal S, Lal R, Lal BN.",Roxithromycin,Single Group,0,Parasitological,Unspecified,vl,
United Kingdom,52.881574,,"244",https://clinicaltrials.gov/ct2/show/NCT03929016,,NCT03929016,United Kingdom - site unknown,56,,DNDI-0690,Single Oral Dose Escalation Study of DNDI-0690 in Healthy Male Subjects,Europe,-1.143834,Active,Sharan Sidhu,"",Dose finding,0,Unspecified,No,vl,
India (IND),26.118589,Spleen/bone,"76",http://www.ncbi.nlm.nih.gov/pubmed/12135285,12135284,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",84,2002,Liposomal Amphotericin B (L-AmB),Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,
Ethiopia (ETH),12.589413,Spleen/bone/lymph,"106",http://www.ncbi.nlm.nih.gov/pubmed/22724032,22724032,NCT00255570,"Gondar University Hospital, Amhara State, Ethiopia",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,37.44205,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Sudan, Kenya"
Ethiopia (ETH),12.589413,Spleen/bone/lymph,"106",http://www.ncbi.nlm.nih.gov/pubmed/22724032,22724032,NCT00255570,"Gondar University Hospital, Amhara State, Ethiopia",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,37.44205,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Sudan, Kenya"
India (IND),26.118677,,"239",,,CTRI/2017/03/007993,"Kala Azar Medical Research Center, Bihar, India",48,,Liposomal Amphotericin B (L-AmB),A comparative study to monitor the safety of Amphotericin 50mg per vial A and Ambisome (amphotericin b) 50 mg per vial B in 48 patients,India Subcontinent,85.400933,Unknown,Kirki Patel,"",Comparative,1,Unspecified,Yes,vl,
Bangladesh (BGD),24.742748,Bone/serological,"146",https://www.ncbi.nlm.nih.gov/pubmed/1645930,1645929,-9,"Mymensingh District, Bangladesh",1273,1991,Sodium stibogluconate,Positive response to sodium antimony gluconate administration in visceral leishmaniasis seropositive patients.,India Subcontinent,90.408589,Published,"Chowdhury S, Haque F, al-Masum A, el Harith A, Karim E.",Sodium stibogluconate,Single Group,0,Mixed,Unspecified,vl,
India (IND),26.118589,Spleen,"37",http://www.ncbi.nlm.nih.gov/pubmed/14727209,14727208,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",153,2004,Amphotericin B deoxycholate,Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.,India Subcontinent,85.400719,Published,"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.",Amphotericin B deoxycholate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"37",http://www.ncbi.nlm.nih.gov/pubmed/14727209,14727208,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",153,2004,Amphotericin B lipid complex (ABLC),Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.,India Subcontinent,85.400719,Published,"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.",Amphotericin B deoxycholate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"37",http://www.ncbi.nlm.nih.gov/pubmed/14727209,14727208,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",153,2004,Liposomal Amphotericin B (L-AmB),Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.,India Subcontinent,85.400719,Published,"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.",Amphotericin B deoxycholate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,No,vl,
India (IND),25.602357,Bone,"131",http://www.ncbi.nlm.nih.gov/pubmed/20065048,20065047,-9,Nalanda Medical College,605,2010,Amphotericin B - formulation unknown,"Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.",India Subcontinent,85.197018,Published,"Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP.",Amphotericin B,Dose finding,0,Parasitological,No,vl,
Nepal (NPL),26.80877,Spleen/bone,"148",http://www.ncbi.nlm.nih.gov/pubmed/15228259,15228259,-9,"B. P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal",120,2003,Sodium stibogluconate,Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.,India Subcontinent,87.262131,Published,"Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S.",Sodium stibogluconate,Single Group,0,Parasitological,Yes,vl,
India (IND),25.6141,Spleen,"35",http://www.ncbi.nlm.nih.gov/pubmed/10492771,10492770,-1,"Kala-azar Research Centre of Balaji Utthan Sansthan, Patna.",938,1999,Amphotericin B deoxycholate,Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases.,India Subcontinent,85.14227,Published,"Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A.",Amphotericin B deoxycholate,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen/bone,"145",http://www.ncbi.nlm.nih.gov/pubmed/16130614,16130613,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",182,2005,Sodium stibogluconate,Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.,India Subcontinent,85.195326,Published,"Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.",Sodium stibogluconate,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"175",http://www.ncbi.nlm.nih.gov/pubmed/25233347,25233347, NCT00876825,Patna Medical College Hospital,500,2014,Amphotericin B lipid emulsion (ABLE),"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.",India Subcontinent,85.159811,Published,"Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P.",Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"175",http://www.ncbi.nlm.nih.gov/pubmed/25233347,25233347, NCT00876825,Patna Medical College Hospital,500,2014,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.",India Subcontinent,85.159811,Published,"Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P.",Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),25.92536,,"236",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Saran,1761,2018,Miltefosine,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.809842,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.92536,,"236",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Saran,1761,2018,Liposomal Amphotericin B (L-AmB),"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.809842,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.92536,,"236",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Saran,1761,2018,Paromomycin,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.809842,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.620021,Spleen,"43",https://www.ncbi.nlm.nih.gov/pubmed/1659240,1659239,-1,Patna Medical College Hospital,312,1991,Sodium stibogluconate,Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M, Pandey AK.",Sodium stibogluconate; Pentamidine,Dose finding,1,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen,"43",https://www.ncbi.nlm.nih.gov/pubmed/1659240,1659239,-1,Patna Medical College Hospital,312,1991,Pentamidine isethionate,Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M, Pandey AK.",Sodium stibogluconate; Pentamidine,Dose finding,1,Parasitological,Unspecified,vl,
India (IND),26.128258,,"190",,,CTRI/2009/091/000058,"Kala-Azar Research Centre, Brahmpura, Muzaffarpur,Bihar,India",,,Liposomal Amphotericin B (L-AmB),"A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul (Amphotericin B Emulsion) As Compared To AmBisome In Patients Of Visceral Leishmaniasis (Kala Azar)",India Subcontinent,85.368128,Completed,T. K. Jha,Liposomal Amphotericin B,Comparative,1,Mixed,Unspecified,vl,
India (IND),26.118589,Spleen,"95",http://www.ncbi.nlm.nih.gov/pubmed/10897370,10897369,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",70,2000,Amphotericin B lipid emulsion (ABLE),"Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.",India Subcontinent,85.400719,Published,"Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW.",Amphotericin B deoxycholate,Single Group,0,Parasitological,No,vl,
Uganda (UGA),1.954237,Spleen/bone/lymph,"101",http://www.ncbi.nlm.nih.gov/pubmed/22724030,22724030,NCT00255568,"Amudat Hospital, Uganda",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,34.945197,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Sudan, Kenya"
Uganda (UGA),1.954237,Spleen/bone/lymph,"101",http://www.ncbi.nlm.nih.gov/pubmed/22724030,22724030,NCT00255568,"Amudat Hospital, Uganda",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,34.945197,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Sudan, Kenya"
Sudan (SDN),15.500654,,"266",https://pubmed.ncbi.nlm.nih.gov/33781913/,33781913,NCT02894008,Sudan - site unknown,24,2021,ChAd63-KH Vaccine,Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.,Eastern Africa,32.559898,Published,"ounis BM, Osman M, Khalil EAG, Santoro F, Furini S, Wiggins R, Keding A, Carraro M, Musa AEA, Abdarahaman MAA, Mandefield L, Bland M, Aebischer T, Gabe R, Layton AM, Lacey CJN, Kaye PM, Musa AM. ","",Non-randomised multi-arm,0,Mixed,No,pkdl,
Brazil (BRA),-12.993413,Spleen/bone,"126",http://www.ncbi.nlm.nih.gov/pubmed/9615495,9615494,-9,"Hospital Universitario Professor Edgard Santos, Brazil",87,1998,Liposomal Amphotericin B (L-AmB),Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.,South America,-38.522392,Published,"Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,Unspecified,vl,"India, Kenya"
Bangladesh (BGD),24.46026,Spleen/bone,"197",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558064, NCT01122773,"Gafargaon Hospital, Gafargaon,Mymensingh, Bangladesh",602,2017,Miltefosine,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.547066,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.46026,Spleen/bone,"197",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558064, NCT01122773,"Gafargaon Hospital, Gafargaon,Mymensingh, Bangladesh",602,2017,Liposomal Amphotericin B (L-AmB),"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.547066,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.46026,Spleen/bone,"197",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558064, NCT01122773,"Gafargaon Hospital, Gafargaon,Mymensingh, Bangladesh",602,2017,Paromomycin,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.547066,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
India (IND),25.599832,,"240",,,CTRI/2017/03/007993,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",47,,Liposomal Amphotericin B (L-AmB),A comparative study to monitor the safety of Amphotericin 50mg per vial A and Ambisome (amphotericin b) 50 mg per vial B in 48 patients,India Subcontinent,85.195326,Unknown,Kirki Patel,"",Comparative,1,Unspecified,Yes,vl,
India (IND),19.001527,Spleen/bone,"51",http://www.ncbi.nlm.nih.gov/pubmed/10492770,10492769,-9,"King Edward Memorial Hospital , Mumbai",63,1999,Liposomal Amphotericin B (L-AmB),Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis.,India Subcontinent,72.839677,Published,"Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, Kshirsagar NA.",Liposomal Amphotericin B,Dose finding,1,Parasitological,Unspecified,vl,
France (FRA),37.513805,Bone,"21",http://www.ncbi.nlm.nih.gov/pubmed/8708370,8708370,-9,Istituto Malattie Infettive Universita Degli Studi Di Catania,10,1996,Liposomal Amphotericin B (L-AmB),Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).,Mediterranean,15.07061,Published,"Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN.",Amphotericin B,Single Group,1,Parasitological,Yes,vl,"Portugal, Tunisia, France"
India (IND),25.599832,Spleen/bone/serological,"83",http://www.ncbi.nlm.nih.gov/pubmed/22174723,22174723,NCT00604956,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",494,2011,Paromomycin,Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India.,India Subcontinent,85.195326,Published,"Sinha PK, Jha TK, Thakur CP, Nath D, Mukherjee S, Aditya AK, Sundar S.",Paromomycin,Single Group,0,Mixed,No,vl,
Kenya (KEN),-1.313005,Spleen,"80",http://www.ncbi.nlm.nih.gov/pubmed/7888531,7888530,-9,Kenya Medical Research institute,16,1994,Sitamaquine,Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis.,Eastern Africa,36.803282,Published,"Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM, et al.",Sitamaquine,Dose finding,0,Parasitological,No,vl,
India (IND),25.274455,Spleen,"15",http://www.ncbi.nlm.nih.gov/pubmed/10707104,10707104,-9,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",45,1999,Miltefosine,Oral treatment of visceral leishmaniasis with miltefosine.,India Subcontinent,82.997337,Published,"Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW.",Miltefosine,Dose finding,0,Parasitological,No,vl,
India (IND),25.620021,Spleen,"49",http://www.ncbi.nlm.nih.gov/pubmed/9797830,9797829,-9,Patna Medical College Hospital,80,1998,Sodium stibogluconate,"Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.",India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK.",Sodium stibogluconate,Single Group,1,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"157",http://www.ncbi.nlm.nih.gov/pubmed/6087516,6087515,-9,Patna Medical College Hospital,750,1984,Sodium stibogluconate,"Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).",India Subcontinent,85.159811,Published,Thakur CP.,Sodium stibogluconate; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"157",http://www.ncbi.nlm.nih.gov/pubmed/6087516,6087515,-9,Patna Medical College Hospital,750,1984,Pentamidine,"Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).",India Subcontinent,85.159811,Published,Thakur CP.,Sodium stibogluconate; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen/bone,"150",http://www.ncbi.nlm.nih.gov/pubmed/11584935,11584934,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",158,2001,Allopurinol,A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.,India Subcontinent,85.195326,Published,"Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, Siddiqui NA, Kar SK.",Allopurinol; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen/bone,"150",http://www.ncbi.nlm.nih.gov/pubmed/11584935,11584934,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",158,2001,Pentamidine,A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.,India Subcontinent,85.195326,Published,"Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, Siddiqui NA, Kar SK.",Allopurinol; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.128258,Unknown,"153",http://www.ncbi.nlm.nih.gov/pubmed/9081959,9081958,-9,"Kala-Azar Research Centre, Brahmpura, Muzaffarpur,Bihar,India",128,1995,levamisole,Combination therapy in Kala-azar.,India Subcontinent,85.368128,Published,"Singh NK, Jha TK, Singh IJ, Jha S.",Ketoconazole; Sodium stibogluconate; Allopurinol; Levamisole,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.128258,Unknown,"153",http://www.ncbi.nlm.nih.gov/pubmed/9081959,9081958,-9,"Kala-Azar Research Centre, Brahmpura, Muzaffarpur,Bihar,India",128,1995,Sodium stibogluconate,Combination therapy in Kala-azar.,India Subcontinent,85.368128,Published,"Singh NK, Jha TK, Singh IJ, Jha S.",Ketoconazole; Sodium stibogluconate; Allopurinol; Levamisole,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.128258,Unknown,"153",http://www.ncbi.nlm.nih.gov/pubmed/9081959,9081958,-9,"Kala-Azar Research Centre, Brahmpura, Muzaffarpur,Bihar,India",128,1995,Ketoconazole,Combination therapy in Kala-azar.,India Subcontinent,85.368128,Published,"Singh NK, Jha TK, Singh IJ, Jha S.",Ketoconazole; Sodium stibogluconate; Allopurinol; Levamisole,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.128258,Unknown,"153",http://www.ncbi.nlm.nih.gov/pubmed/9081959,9081958,-9,"Kala-Azar Research Centre, Brahmpura, Muzaffarpur,Bihar,India",128,1995,Allopurinol,Combination therapy in Kala-azar.,India Subcontinent,85.368128,Published,"Singh NK, Jha TK, Singh IJ, Jha S.",Ketoconazole; Sodium stibogluconate; Allopurinol; Levamisole,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"208",,,NCT01437020,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",0,,Liposomal Amphotericin B (L-AmB),SCH708980 With and Without AmBisome for Visceral Leishmaniasis,India Subcontinent,85.400719,Withdrawn,"Shyam Sundar, David Sacks",Liposomal Amphotericin B,Dose finding,0,Parasitological,Unspecified,vl,
United States of America (USA),38.998104,Unspecified,"246",https://clinicaltrials.gov/ct2/show/study/NCT00662012,,NCT00662012,Walter Reed Army Medical Center,414,,Sodium stibogluconate,Sodium Stibogluconate Treatment of Leishmaniasis,North America,-77.094372,Not Published,Glenn Wortman,"",Single Group,0,Mixed,Unspecified,vl,
India (IND),26.118589,Spleen,"117",http://www.ncbi.nlm.nih.gov/pubmed/7611562,7611561,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",34,1995,Amphotericin B - formulation unknown,"Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.",India Subcontinent,85.400719,Published,"Jha TK, Giri YN, Singh TK, Jha S.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Bangladesh (BGD),24.742748,Serological,"172",http://www.ncbi.nlm.nih.gov/pubmed/26496649,26496649,NCT01328458,"Mymensingh District, Bangladesh",120,2015,Paromomycin,Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.,India Subcontinent,90.408589,Published,"Jamil KM, Haque R, Rahman R, Faiz MA, Bhuiyan AT, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan MA, Khan MM, Ghosh RS.",Paromomycin,Single Group,0,Serological,No,vl,
India (IND),25.620021,Spleen,"48",http://www.ncbi.nlm.nih.gov/pubmed/7867140,7867139,-1,Patna Medical College Hospital,80,1994,Amphotericin B deoxycholate,Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK.",Amphotericin B,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"18",http://www.ncbi.nlm.nih.gov/pubmed/18664241,18664241,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",45,2008,Amphotericin B lipid emulsion (ABLE),Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.,India Subcontinent,85.400719,Published,"Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M.",Amphotericin B; Amphotericin B lipid emulsion,Dose finding,0,Parasitological,No,vl,
India (IND),25.613897,,"189",,,CTRI/2009/091/000058,"Balaji Uthan Sansthan, Patna, India",,,Liposomal Amphotericin B (L-AmB),"A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul (Amphotericin B Emulsion) As Compared To AmBisome In Patients Of Visceral Leishmaniasis (Kala Azar)",India Subcontinent,85.139591,Completed,C. P. Thakur,Liposomal Amphotericin B,Comparative,1,Mixed,Unspecified,vl,
Bangladesh (BGD),24.760615,Serological,"176",http://www.ncbi.nlm.nih.gov/pubmed/25104637,25104637,CTRN12612000367842,"Muktagacha upazila hospital, Bangladesh",300,2014,Liposomal Amphotericin B (L-AmB),Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.,India Subcontinent,90.269615,Published,"Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B.",Liposomal Amphotericin B,Single Group,0,Serological,Unspecified,vl,
India (IND),26.118589,Spleen,"19",http://www.ncbi.nlm.nih.gov/pubmed/11049800,11049800,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",54,2000,Miltefosine,Short-course of oral miltefosine for treatment of visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P, Murray HW.",Miltefosine,Dose finding,0,Parasitological,No,vl,
Bangladesh (BGD),24.742748,,"185",,,ACTRN12609001029280,"Mymensingh District, Bangladesh",35,,Liposomal Amphotericin B (L-AmB),Liposomal amphotericin B for the treatment of Bangladeshi patients with visceral leishmaniasis,India Subcontinent,90.408589,Completed,Mahmudur Rahman,Liposomal Amphotericin B,Single Group,0,Mixed,Unspecified,vl,
Sudan (SDN),14.024307,,"264",,,NCT03399955,"Prof Elhassan Centre for Tropical Medicine, Gedaref, Sudan",110,,Miltefosine,Short Course Regimens for Treatment of PKDL (Sudan)  ,Eastern Africa,35.368568,Not Published,"Brima Musa, Severine Monnerat, Gina M Ouattara","",RCT,0,Mixed,Unspecified,pkdl,
Sudan (SDN),14.024307,,"264",,,NCT03399955,"Prof Elhassan Centre for Tropical Medicine, Gedaref, Sudan",110,,Liposomal Amphotericin B (L-AmB),Short Course Regimens for Treatment of PKDL (Sudan)  ,Eastern Africa,35.368568,Not Published,"Brima Musa, Severine Monnerat, Gina M Ouattara","",RCT,0,Mixed,Unspecified,pkdl,
Sudan (SDN),14.024307,,"264",,,NCT03399955,"Prof Elhassan Centre for Tropical Medicine, Gedaref, Sudan",110,,Paromomycin,Short Course Regimens for Treatment of PKDL (Sudan)  ,Eastern Africa,35.368568,Not Published,"Brima Musa, Severine Monnerat, Gina M Ouattara","",RCT,0,Mixed,Unspecified,pkdl,
Ethiopia (ETH),12.589413,Spleen/bone/lymph,"64",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Gondar University Hospital, Amhara State, Ethiopia",270,2010,Sodium stibogluconate,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,37.44205,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Kenya"
Ethiopia (ETH),12.589413,Spleen/bone/lymph,"64",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Gondar University Hospital, Amhara State, Ethiopia",270,2010,Paromomycin,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,37.44205,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Kenya"
India (IND),22.311946,Spleen/bone/serological,"127",http://www.ncbi.nlm.nih.gov/pubmed/23087514,23087513,-9,"Canning Sub Divisional Hospital,South 24 Parganas district, West Bengal",71,2012,Miltefosine,"Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.",India Subcontinent,88.641284,Published,"Patra P, Guha SK, Maji AK, Saha P, Ganguly S, Chakraborty A, Kundu PK, Sarker S, Ray K.",Miltefosine,Single Group,0,Mixed,No,vl,
India (IND),26.118589,Spleen,"165",http://www.ncbi.nlm.nih.gov/pubmed/9675482,9675482,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",28,1998,Atovaquone,Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar.,India Subcontinent,85.400719,Published,"Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, Murray H.",Atovaquone ; Fluconazole,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"165",http://www.ncbi.nlm.nih.gov/pubmed/9675482,9675482,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",28,1998,Fluconazole,Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar.,India Subcontinent,85.400719,Published,"Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, Murray H.",Atovaquone ; Fluconazole,Comparative,0,Parasitological,Unspecified,vl,
India (IND),22.574963,,"238",,,CTRI/2017/03/007993,"School of Tropical Medicine, Calcutta Medical College, Kolkata, India",48,,Liposomal Amphotericin B (L-AmB),A comparative study to monitor the safety of Amphotericin 50mg per vial A and Ambisome (amphotericin b) 50 mg per vial B in 48 patients,India Subcontinent,88.357584,Unknown,Kirki Patel,"",Comparative,1,Unspecified,Yes,vl,
India (IND),26.118589,Serological,"179",,,NCT01566552,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",1300,,Liposomal Amphotericin B (L-AmB),Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis,India Subcontinent,85.400719,Unknown,Shyam Sundar,Liposomal Amphotericin B,Single Group,0,Serological,Unspecified,vl,
Sudan (SDN),13.845118,Spleen/lymph/serological,"119",http://www.ncbi.nlm.nih.gov/pubmed/10886793,10886792,-9,"Kassab Hospital, Ministry of Health, Gedaref State",516,2000,Sodium stibogluconate,A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.,Eastern Africa,35.422757,Published,"Veeken H, Ritmeijer K, Seaman J, Davidson R.",Sodium stibogluconate,Comparative,0,Mixed,Unspecified,vl,
India (IND),26.121473,,"263",,,CTRI/2017/04/008421,"Kala-Azar Medical Research Center, Muzaffarpur, India; Rajendra Memorial Research Institute of Medical Sciences, Patna, India",110,,Miltefosine,"An Open label, Randomized, Clinical Trial of Two Regimens to Assess the Safety and Efficacy for  Treatment of PKDL Patients in the Indian subcontinent",India Subcontinent,85.368752,Not Published,"Shyam Sundar, Krishna Pandey, Vishal Goyal","",RCT,0,Mixed,Unspecified,pkdl,Bangladesh (BGD)
India (IND),26.121473,,"263",,,CTRI/2017/04/008421,"Kala-Azar Medical Research Center, Muzaffarpur, India; Rajendra Memorial Research Institute of Medical Sciences, Patna, India",110,,Liposomal Amphotericin B (L-AmB),"An Open label, Randomized, Clinical Trial of Two Regimens to Assess the Safety and Efficacy for  Treatment of PKDL Patients in the Indian subcontinent",India Subcontinent,85.368752,Not Published,"Shyam Sundar, Krishna Pandey, Vishal Goyal","",RCT,0,Mixed,Unspecified,pkdl,Bangladesh (BGD)
India (IND),26.118589,Spleen/bone,"17",http://www.ncbi.nlm.nih.gov/pubmed/19407109,19407109,NCT00497601,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",60,2009,Amphotericin B lipid emulsion (ABLE),Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J.",Amphotericin B lipid emulsion,Dose finding,0,Parasitological,No,vl,
Kenya (KEN),-1.313005,Spleen,"26",http://www.ncbi.nlm.nih.gov/pubmed/6309993,6309993,-9,Kenya Medical Research institute,30,1983,Sodium stibogluconate,A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya.,Eastern Africa,36.803282,Published,"Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JB, Chunge C, Bryceson AD.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
Sudan (SDN),13.845118,Spleen/bone/lymph,"193",https://www.ncbi.nlm.nih.gov/pubmed/27627655,27627655,NCT010667444,"Kassab Hospital, Ministry of Health, Gedaref State",183,2016,Sodium stibogluconate,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.422757,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
Sudan (SDN),13.845118,Spleen/bone/lymph,"193",https://www.ncbi.nlm.nih.gov/pubmed/27627655,27627655,NCT010667444,"Kassab Hospital, Ministry of Health, Gedaref State",183,2016,Miltefosine,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.422757,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
Sudan (SDN),13.845118,Spleen/bone/lymph,"193",https://www.ncbi.nlm.nih.gov/pubmed/27627655,27627655,NCT010667444,"Kassab Hospital, Ministry of Health, Gedaref State",183,2016,Liposomal Amphotericin B (L-AmB),Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.422757,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
India (IND),26.385046,Spleen/bone,"78",http://www.ncbi.nlm.nih.gov/pubmed/11280167,11280166,-9,"Jale Village, Darbhanga, Bihar",309,2001,Amphotericin B deoxycholate,"Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.",India Subcontinent,85.72721,Published,"Thakur CP, Ahmed S.",Amphotericin B deoxycholate,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen,"44",https://www.ncbi.nlm.nih.gov/pubmed/1659240,1659239,-1,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",312,1991,Sodium stibogluconate,Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.,India Subcontinent,85.195326,Published,"Thakur CP, Kumar M, Pandey AK.",Sodium stibogluconate; Pentamidine,Dose finding,1,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen,"44",https://www.ncbi.nlm.nih.gov/pubmed/1659240,1659239,-1,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",312,1991,Pentamidine isethionate,Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.,India Subcontinent,85.195326,Published,"Thakur CP, Kumar M, Pandey AK.",Sodium stibogluconate; Pentamidine,Dose finding,1,Parasitological,Unspecified,vl,
India (IND),25.274455,Spleen/bone,"69",http://www.ncbi.nlm.nih.gov/pubmed/17582068,17582068, NCT00216347,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",667,2007,Amphotericin B - formulation unknown,Injectable paromomycin for Visceral leishmaniasis in India.,India Subcontinent,82.997337,Published,"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.",Amphotericin B; Paromomycin,Comparative,1,Parasitological,No,vl,
India (IND),25.274455,Spleen/bone,"69",http://www.ncbi.nlm.nih.gov/pubmed/17582068,17582068, NCT00216347,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",667,2007,Paromomycin,Injectable paromomycin for Visceral leishmaniasis in India.,India Subcontinent,82.997337,Published,"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.",Amphotericin B; Paromomycin,Comparative,1,Parasitological,No,vl,
India (IND),25.256922,Spleen,"249",,,,"Jawahar Lal Nehru Medical College and Hospital, Bhagalpur, Bihar",160,,Miltefosine,,India Subcontinent,86.994025,Published,,"",Single Group,0,Serological,No,vl,
Ethiopia (ETH),8.153206,,"230",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Ethiopia - Site Unknown,3126,2017,Sodium stibogluconate,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,38.984647,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Sudan, Uganda,Kenya"
Ethiopia (ETH),8.153206,,"230",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Ethiopia - Site Unknown,3126,2017,Paromomycin,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,38.984647,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Sudan, Uganda,Kenya"
Bangladesh (BGD),24.403416,Spleen/bone,"196",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558063, NCT01122772,"Bhaluka Hospital, Bhaluka,Mymensingh, Bangladesh",602,2017,Miltefosine,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.380768,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.403416,Spleen/bone,"196",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558063, NCT01122772,"Bhaluka Hospital, Bhaluka,Mymensingh, Bangladesh",602,2017,Liposomal Amphotericin B (L-AmB),"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.380768,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.403416,Spleen/bone,"196",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558063, NCT01122772,"Bhaluka Hospital, Bhaluka,Mymensingh, Bangladesh",602,2017,Paromomycin,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.380768,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
India (IND),26.118589,Spleen,"32",http://www.ncbi.nlm.nih.gov/pubmed/21129763,21129763,NCT00371996,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",135,2011,Miltefosine,Ambisome plus miltefosine for Indian patients with kala-azar.,India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B.",Miltefosine; Liposomal Amphotericin B,Single Group,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"32",http://www.ncbi.nlm.nih.gov/pubmed/21129763,21129763,NCT00371996,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",135,2011,Liposomal Amphotericin B (L-AmB),Ambisome plus miltefosine for Indian patients with kala-azar.,India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B.",Miltefosine; Liposomal Amphotericin B,Single Group,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"58",http://www.ncbi.nlm.nih.gov/pubmed/1649791,1649790,-1,Patna Medical College Hospital,312,1991,Sodium stibogluconate,Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M, Pandey AK.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"98",http://www.ncbi.nlm.nih.gov/pubmed/12955642,12955641,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",203,2003,Liposomal Amphotericin B (L-AmB),Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.",Liposomal Amphotericin B,Single Group,1,Parasitological,No,vl,
India (IND),22.574963,Spleen/bone,"118",http://www.ncbi.nlm.nih.gov/pubmed/20668545,20668545,CTRI/2009/091/000765,"School of Tropical Medicine Kolkata, India",30,2010,Liposomal Amphotericin B (L-AmB),A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy.,India Subcontinent,88.357584,Published,"Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP.",Amphotericin B; Liposomal Amphotericin B,Dose finding,0,Parasitological,Unspecified,vl,
Portugal,39.569589,Bone,"22",http://www.ncbi.nlm.nih.gov/pubmed/8708370,8708370,-9,Portugal - Site Unknown,10,1996,Liposomal Amphotericin B (L-AmB),Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).,Mediterranean,-8.206907,Published,"Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN.",Amphotericin B,Single Group,1,Parasitological,Yes,vl,"Tunisia, France"
India (IND),26.131728,Bone,"121",http://www.ncbi.nlm.nih.gov/pubmed/7983994,7983993,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",80,1994,Sodium stibogluconate,Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.,India Subcontinent,85.896955,Published,"Mishra M, Biswas UK, Jha AM, Khan AB.",Sodium stibogluconate; Amphotericin B deoxycholate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.131728,Bone,"121",http://www.ncbi.nlm.nih.gov/pubmed/7983994,7983993,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",80,1994,Amphotericin B - formulation unknown,Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.,India Subcontinent,85.896955,Published,"Mishra M, Biswas UK, Jha AM, Khan AB.",Sodium stibogluconate; Amphotericin B deoxycholate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.818891,Spleen,"156",http://www.ncbi.nlm.nih.gov/pubmed/7883660,7883659,-9,"Vaishali District, Bihar, India",25,1994,Amphotericin B - formulation unknown,Treatment of visceral Leishmaniasis unresponsive to pentamidine with amphotericin B.,India Subcontinent,85.343484,Published,Giri OP.,Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Kenya (KEN),-1.313005,Spleen/bone/lymph,"66",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Kenya Medical Research institute, Nairobi, Kenya",270,2010,Sodium stibogluconate,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,36.803282,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Ethiopia"
Kenya (KEN),-1.313005,Spleen/bone/lymph,"66",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Kenya Medical Research institute, Nairobi, Kenya",270,2010,Paromomycin,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,36.803282,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Ethiopia"
Ethiopia (ETH),13.560317,Spleen/serological,"57",http://www.ncbi.nlm.nih.gov/pubmed/11816443,11816442,-9,Dansha Health Center,199,2001,Sodium stibogluconate,Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.,Eastern Africa,36.96427,Published,"Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN.",Sodium stibogluconate,Comparative,0,Mixed,Yes,vl,
India (IND),25.599832,Spleen/bone,"184",,,CTRI/2010/091/000299,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",180,,Liposomal Amphotericin B (L-AmB),"Rationalization of single dose 10 mg/kg/bw and 15 mg /kg/bw as compared to 5 mg/kg/bw for four days of Liposomal Amphotericin B with special reference to efficacy and safety profile for treatment of visceral leishmaniasis in Bihar, India�",India Subcontinent,85.195326,Active,Prabhat Kumar Sinha ,Liposomal Amphotericin B,Comparative,0,Parasitological,Unspecified,vl,
Sudan (SDN),13.845118,Spleen/bone/lymph,"104",http://www.ncbi.nlm.nih.gov/pubmed/22724030,22724030,NCT00255568,"Kassab Hospital, Ministry of Health, Gedaref State, Sudan",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,35.422757,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Kenya"
Sudan (SDN),13.845118,Spleen/bone/lymph,"104",http://www.ncbi.nlm.nih.gov/pubmed/22724030,22724030,NCT00255568,"Kassab Hospital, Ministry of Health, Gedaref State, Sudan",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,35.422757,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Kenya"
India (IND),27.259035,Unspecified,"248",,,,"Bihar, India -  Site Unknown",150,,Miltefosine,,India Subcontinent,84.017529,Not Published,,"",Comparative,0,Mixed,Yes,vl,
India (IND),27.259035,Unspecified,"248",,,,"Bihar, India -  Site Unknown",150,,Amphotericin B - formulation unknown,,India Subcontinent,84.017529,Not Published,,"",Comparative,0,Mixed,Yes,vl,
India (IND),25.620021,Spleen/bone,"52",http://www.ncbi.nlm.nih.gov/pubmed/10492770,10492769,-9,Patna Medical College Hospital,63,1999,Liposomal Amphotericin B (L-AmB),Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis.,India Subcontinent,85.159811,Published,"Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, Kshirsagar NA.",Liposomal Amphotericin B,Dose finding,1,Parasitological,Unspecified,vl,
Spain (ESP),40.475266,Spleen/bone/liver,"3",http://www.ncbi.nlm.nih.gov/pubmed/12888588,12888588,-9,"Servicio de Enfermedades Infecciosas, Hospital Carlos III",57,2003,Meglumine antimoniate,Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.,Mediterranean,-3.6987343,Published,"Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M,López-Vélez R, Alvar J; Spanish HIV-Leishmania Study Group.",Amphotericin B lipid complex; Meglumine antimoniate,Comparative,0,Parasitological,Yes,vl,
Spain (ESP),40.475266,Spleen/bone/liver,"3",http://www.ncbi.nlm.nih.gov/pubmed/12888588,12888588,-9,"Servicio de Enfermedades Infecciosas, Hospital Carlos III",57,2003,Amphotericin B lipid complex (ABLC),Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.,Mediterranean,-3.6987343,Published,"Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M,López-Vélez R, Alvar J; Spanish HIV-Leishmania Study Group.",Amphotericin B lipid complex; Meglumine antimoniate,Comparative,0,Parasitological,Yes,vl,
India (IND),26.118589,Spleen,"151",http://www.ncbi.nlm.nih.gov/pubmed/10999087,10999086,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",58,1999,Amphotericin B lipid complex (ABLC),Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW.",Amphotericin B lipid complex,Dose finding,0,Parasitological,No,vl,
India (IND),25.599832,Spleen/bone,"178",,,CTRI/2015/05/005807,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",112,,Miltefosine,A randomized trial of AmBisome single therapy and combination of AmBisome and miltefosine for the treatment of Kala Azar in HIV positive patients in India,India Subcontinent,85.195326,Active,Krishna Pandey,Miltefosine; Liposomal Amphotericin B,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen/bone,"178",,,CTRI/2015/05/005807,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",112,,Liposomal Amphotericin B (L-AmB),A randomized trial of AmBisome single therapy and combination of AmBisome and miltefosine for the treatment of Kala Azar in HIV positive patients in India,India Subcontinent,85.195326,Active,Krishna Pandey,Miltefosine; Liposomal Amphotericin B,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"173",http://www.ncbi.nlm.nih.gov/pubmed/25510716,25510716,CTRI/2011/11/002146,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",30,2015,Liposomal Amphotericin B (L-AmB),Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.,India Subcontinent,85.400719,Published,"Sundar S, Singh A, Rai M, Chakravarty J.",Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Spain (ESP),41.427477,Unknown,"130",http://www.ncbi.nlm.nih.gov/pubmed/14636518,14636517,-1,Hospital Infantil Vall D'Hebron,32,2003,Liposomal Amphotericin B (L-AmB),[Short course treatment for visceral leishmaniasis with liposomal amphotericin B in immunocompetent patients].,Mediterranean,2.141047,Published,"Figueras Nadal MC, García de Miguel MJ, Asensi Botet F, Velasco Bernardo R, Canals Baeza A, Ausín Aoiz I.",Liposomal Amphotericin B,Single Group,0,Unspecified,No,vl,
India (IND),25.613271,Spleen,"33",http://www.ncbi.nlm.nih.gov/pubmed/7778156,7778155,-1,Tripolia social service hospital,136,1995,Sodium stibogluconate,Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.,India Subcontinent,85.18754,Published,"Thakur CP, Bhowmick S, Dolfi L, Olliaro P.",Sodium stibogluconate; Paromomycin,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),25.613271,Spleen,"33",http://www.ncbi.nlm.nih.gov/pubmed/7778156,7778155,-1,Tripolia social service hospital,136,1995,Paromomycin,Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.,India Subcontinent,85.18754,Published,"Thakur CP, Bhowmick S, Dolfi L, Olliaro P.",Sodium stibogluconate; Paromomycin,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),37.513805,Unknown,"24",http://www.ncbi.nlm.nih.gov/pubmed/7811891,7811891,-1,Istituto Malattie Infettive Universita Degli Studi Di Catania,10,1994,Liposomal Amphotericin B (L-AmB),Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B.,Mediterranean,15.07061,Published,"Davidson RN, Russo R.",Amphotericin B,Single Group,0,Unspecified,Yes,vl,
India (IND),22.575014,Spleen,"171",http://www.ncbi.nlm.nih.gov/pubmed/26526927,26526927,CTRI/2009/091/000765,"Calcutta School of Tropical Medicine, Calcutta",120,2016,Liposomal Amphotericin B (L-AmB),Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™).,India Subcontinent,88.359621,Published,"Goswami RP, Goswami RP, Das S, Satpati A, Rahman M.",Liposomal Amphotericin B,Comparative,0,Parasitological,No,vl,
Sudan (SDN),13.845118,Spleen/bone/lymph,"89",http://www.ncbi.nlm.nih.gov/pubmed/24454972,24454972, NCT00832210,"Kassab Hospital, Ministry of Health, Gedaref State, Sudan",124,2014,Liposomal Amphotericin B (L-AmB),Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.,Eastern Africa,35.422757,Published,"Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,Ethiopia
Brazil (BRA),-10.056544,Bone,"92",http://www.ncbi.nlm.nih.gov/pubmed/8783691,8783690,-9,Brazil - site unknown,88,1996,Liposomal Amphotericin B (L-AmB),Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).,South America,-53.386253,Published,"Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,"Italy, United Kingdom"
Kenya (KEN),-1.3010129,Spleen,"147",http://www.ncbi.nlm.nih.gov/pubmed/6329011,6329010,-9,Kenyatta National Hospital,16,1984,Sodium stibogluconate,The response of Kenyan kala-azar to treatment with sodium stibogluconate.,Eastern Africa,36.805005,Published,"Rees PH, Kager PA, Wellde BT, Hockmeyer WT.",Sodium stibogluconate,Single Group,0,Parasitological,Unspecified,vl,
Kenya (KEN),-1.313005,Spleen,"28",http://www.ncbi.nlm.nih.gov/pubmed/16282296,16282296,-9,Kenya Medical Research institute,97,2005,Sitamaquine,A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.,Eastern Africa,36.803282,Published,"Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Albert MJ, Horton J.",Sitamaquine,Dose finding,0,Parasitological,No,vl,
Kenya (KEN),-1.313005,Spleen/bone/lymph,"103",http://www.ncbi.nlm.nih.gov/pubmed/22724032,22724032,NCT00255570,"Kenya Medical Research institute, Nairobi, Kenya",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,36.803282,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Sudan"
Kenya (KEN),-1.313005,Spleen/bone/lymph,"103",http://www.ncbi.nlm.nih.gov/pubmed/22724032,22724032,NCT00255570,"Kenya Medical Research institute, Nairobi, Kenya",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,36.803282,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Sudan"
Sudan (SDN),9.6655153,Spleen/bone/lymph,"55",http://www.ncbi.nlm.nih.gov/pubmed/8394862,8394861,-1,"Western Upper Nile, Sudan",200,1993,Sodium stibogluconate,Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.,Eastern Africa,28.873127,Published,"Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
Sudan (SDN),9.6655153,Spleen/bone/lymph,"55",http://www.ncbi.nlm.nih.gov/pubmed/8394862,8394861,-1,"Western Upper Nile, Sudan",200,1993,Paromomycin,Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.,Eastern Africa,28.873127,Published,"Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.131728,Bone,"144",http://www.ncbi.nlm.nih.gov/pubmed/1673013,1673012,-1,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",15,1991,Amphotericin B - formulation unknown,Amphotericin B for second-line treatment of Indian kala-azar.,India Subcontinent,85.896955,Published,"Mishra M, Singh MP, Choudhury D, Singh VP, Khan AB.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Kenya (KEN),0.46502,,"215",,,NCT03129647,"Kimalel Health Centre, Kimalel, Rift Valley, Kenya",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.891689,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
Kenya (KEN),0.46502,,"215",,,NCT03129647,"Kimalel Health Centre, Kimalel, Rift Valley, Kenya",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.891689,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
Kenya (KEN),0.46502,,"215",,,NCT03129647,"Kimalel Health Centre, Kimalel, Rift Valley, Kenya",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.891689,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
Bangladesh (BGD),24.704209,,"199",,,NCT01240473,"Community Based Medical College, Trishal,Mymensingh, Bangladesh",200,,Sodium stibogluconate,"A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh",India Subcontinent,90.388805,Completed,Kazi M Jamil,Sodium stibogluconate,Single Group,0,Mixed,Unspecified,vl,
Sudan (SDN),13.583108,Lymph/serological,"162",http://www.ncbi.nlm.nih.gov/pubmed/16730363,16730363,-1,Um el Kheir Treatment Center,64,2006,Liposomal Amphotericin B (L-AmB),Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.,Eastern Africa,35.087274,Published,"Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R.",Liposomal Amphotericin B,Single Group,0,Mixed,Yes,vl,
Iran (Islamic Republic of) (IRN),29.629926,Serological,"167",http://www.ncbi.nlm.nih.gov/pubmed/19478699,19478699,-9,Shiraz University of Medical Sciences,20,2009,Meglumine antimoniate,Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.,Central Asia,52.521502,Published,"Shahian M, Alborzi A.",Meglumine antimoniate,Single Group,0,Serological,No,vl,
Brazil (BRA),-3.744724,Bone,"205",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Sao José Hospital of Infectious Diseases, Fortaleza, Ceará",378,2017,Meglumine antimoniate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-38.558217,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-3.744724,Bone,"205",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Sao José Hospital of Infectious Diseases, Fortaleza, Ceará",378,2017,Amphotericin B deoxycholate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-38.558217,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-3.744724,Bone,"205",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Sao José Hospital of Infectious Diseases, Fortaleza, Ceará",378,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-38.558217,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
India (IND),25.620021,Spleen,"36",http://www.ncbi.nlm.nih.gov/pubmed/8477210,8477209,-9,Patna Medical College Hospital,300,1993,Amphotericin B deoxycholate,Amphotericin B in resistant kala-azar in Bihar.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Kenya (KEN),1.4369484,Spleen/serological,"40",http://www.ncbi.nlm.nih.gov/pubmed/11417034,11417033,-9,"Ortum Mission Hosppital, West pokot,Kenya",102,2001,Sodium stibogluconate,Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.,Eastern Africa,35.353392,Published,"Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN.",Sodium stibogluconate,Comparative,0,Mixed,Unspecified,vl,
India (IND),26.131569,Spleen/bone,"4",http://www.ncbi.nlm.nih.gov/pubmed/8409490,8409490,-9,Darbhanga Medical College and Hospital,27,1993,Amphotericin B - formulation unknown,Amphotericin B therapy in kala-azar.,India Subcontinent,85.899149,Published,Giri OP.,Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Brazil (BRA),-16.718362,Bone,"203",https://www.ncbi.nlm.nih.gov/pubmed/28662037,28662037,NCT01310741,"Montes Claros State University, Montes Claros",378,2017,Meglumine antimoniate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.877598,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-16.718362,Bone,"203",https://www.ncbi.nlm.nih.gov/pubmed/28662037,28662037,NCT01310741,"Montes Claros State University, Montes Claros",378,2017,Amphotericin B deoxycholate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.877598,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-16.718362,Bone,"203",https://www.ncbi.nlm.nih.gov/pubmed/28662037,28662037,NCT01310741,"Montes Claros State University, Montes Claros",378,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.877598,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
India (IND),26.118677,,"242",,,NCT03636659; CTRI/2018/04/013350,"Kala Azar Medical Research Center, Bihar, India",140,,Liposomal Amphotericin B (L-AmB),Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition,India Subcontinent,85.400933,Completed,"Nagesh Meda, Sajid Mohd, Subhra Lahiri, Krishna Pandey, Shyam Sunda, Dinesh Mondal","",Comparative,1,Serological,No,vl,Bangladesh
Nepal (NPL),26.80877,Unknown,"160",http://www.ncbi.nlm.nih.gov/pubmed/24941345,24941345,-9,"B. P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal",1016,2014,Miltefosine,Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.,India Subcontinent,87.262131,Published,"Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M.",Miltefosine,Single Group,1,Unspecified,Unspecified,vl,India
India (IND),26.118589,Spleen,"47",http://www.ncbi.nlm.nih.gov/pubmed/8627050,8627049,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",25,1996,Amphotericin B lipid complex (ABLC),Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.,India Subcontinent,85.400719,Published,"Sundar S, Murray HW.",Amphotericin B lipid complex,Dose finding,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"123",http://www.ncbi.nlm.nih.gov/pubmed/8758094,8758093,-9,Patna Medical College Hospital,30,1996,Liposomal Amphotericin B (L-AmB),Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.,India Subcontinent,85.159811,Published,"Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P.",Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Brazil (BRA),-19.986212,Bone,"163",http://www.ncbi.nlm.nih.gov/pubmed/24743472,24743472,-9,Eduardo de Menezes Hospital,90,2014,Pentavalent antimonial,Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.,South America,-43.989302,Published,"Cota GF, de Sousa MR, de Mendonça AL, Patrocinio A, Assunção LS, de Faria SR, Rabello A",Amphotericin B; Meglumine antimoniate; Liposomal Amphotericin B,Comparative,0,Parasitological,Yes,vl,
Brazil (BRA),-19.986212,Bone,"163",http://www.ncbi.nlm.nih.gov/pubmed/24743472,24743472,-9,Eduardo de Menezes Hospital,90,2014,Amphotericin B deoxycholate,Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.,South America,-43.989302,Published,"Cota GF, de Sousa MR, de Mendonça AL, Patrocinio A, Assunção LS, de Faria SR, Rabello A",Amphotericin B; Meglumine antimoniate; Liposomal Amphotericin B,Comparative,0,Parasitological,Yes,vl,
Brazil (BRA),-19.986212,Bone,"163",http://www.ncbi.nlm.nih.gov/pubmed/24743472,24743472,-9,Eduardo de Menezes Hospital,90,2014,Liposomal Amphotericin B (L-AmB),Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.,South America,-43.989302,Published,"Cota GF, de Sousa MR, de Mendonça AL, Patrocinio A, Assunção LS, de Faria SR, Rabello A",Amphotericin B; Meglumine antimoniate; Liposomal Amphotericin B,Comparative,0,Parasitological,Yes,vl,
India (IND),25.613897,Bone,"56",http://www.ncbi.nlm.nih.gov/pubmed/15489555,15489554,-9,"Balaji Uthan Sansthan, Patna, India",282,2004,Sodium stibogluconate,"Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.",India Subcontinent,85.139591,Published,"Thakur CP, Narayan S, Ranjan A.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,No,vl,
India (IND),25.613897,Bone,"56",http://www.ncbi.nlm.nih.gov/pubmed/15489555,15489554,-9,"Balaji Uthan Sansthan, Patna, India",282,2004,Amphotericin B - formulation unknown,"Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.",India Subcontinent,85.139591,Published,"Thakur CP, Narayan S, Ranjan A.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,No,vl,
United States of America (USA),38.998104,Unspecified,"247",https://ClinicalTrials.gov/show/NCT00657618,,NCT00657618,Walter Reed Army Medical Center,77,,Sodium stibogluconate,Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis,North America,-77.094372,Not Published,Roseanne Ressner,"",Single Group,0,Mixed,Unspecified,vl,
India (IND),25.599832,Spleen,"84",http://www.ncbi.nlm.nih.gov/pubmed/17624847,17624846,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",1132,2007,Miltefosine,Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.,India Subcontinent,85.195326,Published,"Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK.",Miltefosine,Single Group,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"124",http://www.ncbi.nlm.nih.gov/pubmed/9615495,9615494,-9,"Patna Medical College Hospital, Bihar, India",87,1998,Liposomal Amphotericin B (L-AmB),Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.,India Subcontinent,85.159811,Published,"Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,Unspecified,vl,"Brazil, Kenya"
India (IND),28.566465,Spleen/bone,"8",http://www.ncbi.nlm.nih.gov/pubmed/9282505,9282505,-9,All India Institute of Medical Science,180,1997,Ketoconazole,Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar--a comparative study.,India Subcontinent,77.2097,Published,"Wali JP, Aggarwal P, Nandy A, Singh S, Addy M, Guha SK, Dwivedi SN, Karmarkar MG, Maji AK.",Ketoconazole; Sodium stibogluconate,Comparative,1,Parasitological,Unspecified,vl,
India (IND),28.566465,Spleen/bone,"8",http://www.ncbi.nlm.nih.gov/pubmed/9282505,9282505,-9,All India Institute of Medical Science,180,1997,Sodium stibogluconate,Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar--a comparative study.,India Subcontinent,77.2097,Published,"Wali JP, Aggarwal P, Nandy A, Singh S, Addy M, Guha SK, Dwivedi SN, Karmarkar MG, Maji AK.",Ketoconazole; Sodium stibogluconate,Comparative,1,Parasitological,Unspecified,vl,
Kenya (KEN),1.481702,,"183",https://www.ncbi.nlm.nih.gov/pubmed/30188979,30188979,NCT02431144,"Kacheliba Hospital, Kacheliba, West Pokot, Kenya",30,2018,Miltefosine,"Pharmacokinetics, safety and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial",Eastern Africa,35.01022,Completed,Rashid Juma,Miltefosine,Single Group,1,Parasitological,No,vl,Uganda
India (IND),26.166981,Bone,"59",http://www.ncbi.nlm.nih.gov/pubmed/6868097,6868096,-9,S.K Medical College Hospital,82,1983,Pentamidine isethionate,"Evaluation of diamidine compound (pentamidine isethionate) in the treatment-resistant cases of kala-azar occurring in North Bihar, India.",India Subcontinent,85.391184,Published,Jha TK.,Pentamidine,Single Group,0,Parasitological,Unspecified,vl,
Yemen (YEM),15.699151,Spleen/bone,"141",http://www.ncbi.nlm.nih.gov/pubmed/11426244,11426243,-9,"Saudi Hospital,Hajjh, Republic of Yemen.",32,2001,Sodium stibogluconate,Visceral Leishmaniasis in children in the Yemen.,Central Asia,43.600359,Published,"Haidar NA, Diab AB, El-Sheik AM.",Sodium stibogluconate,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.781675,,"233",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Chapra District Hospital (Saran),1761,2018,Miltefosine,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.730634,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.781675,,"233",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Chapra District Hospital (Saran),1761,2018,Liposomal Amphotericin B (L-AmB),"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.730634,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.781675,,"233",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Chapra District Hospital (Saran),1761,2018,Paromomycin,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,84.730634,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),27.036864,,"245",,,CTRI/2019/04/018673,India -  Site Unknown,140,,Amphotericin B Liposome,"To compare the blood levels and side effects between liposomal Amphotericin B Injection of Sun Pharmaceutical Industries Limited and AmBisomeÂ® of Astellas Pharma US, Inc.",India Subcontinent,83.830117,Active,"Arshad Khuroo, Sharad Kholambe","",Comparative,0,Serological,No,vl,
India (IND),26.166981,Spleen,"143",http://www.ncbi.nlm.nih.gov/pubmed/8979612,8979611,-1,S.K Medical College Hospital,32,1996,Amphotericin B deoxycholate,Amphotericin B in resistant visceral leishmaniasis.,India Subcontinent,85.391184,Published,"Sahay AS, Jha TK.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Uganda (UGA),1.954237,Serological,"87",http://www.ncbi.nlm.nih.gov/pubmed/18186975,18186974,-9,"Amudat Hospital, Uganda",371,2008,Sodium stibogluconate,Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda.,Eastern Africa,34.945197,Published,"Mueller Y, Nguimfack A, Cavailler P, Couffignal S, Rwakimari JB, Loutan L, Chappuis F.",Sodium stibogluconate; Amphotericin B deoxycholate,Single Group,0,Serological,Unspecified,vl,
Uganda (UGA),1.954237,Serological,"87",http://www.ncbi.nlm.nih.gov/pubmed/18186975,18186974,-9,"Amudat Hospital, Uganda",371,2008,Amphotericin B deoxycholate,Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda.,Eastern Africa,34.945197,Published,"Mueller Y, Nguimfack A, Cavailler P, Couffignal S, Rwakimari JB, Loutan L, Chappuis F.",Sodium stibogluconate; Amphotericin B deoxycholate,Single Group,0,Serological,Unspecified,vl,
India (IND),25.620021,Spleen,"2",http://www.ncbi.nlm.nih.gov/pubmed/11137652,11137652,-9,Patna Medical College Hospital,34,2001,Liposomal Amphotericin B (L-AmB),A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.,India Subcontinent,85.159811,Published,Thakur CP.,Amphotericin B deoxycholate; Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Kenya (KEN),-1.313005,Spleen,"71",http://www.ncbi.nlm.nih.gov/pubmed/7828501,7828500,-9,Kenya Medical Research institute,65,1994,Sodium stibogluconate,Is one year follow-up justified in kala-azar post-treatment?,Eastern Africa,36.803282,Published,"Nyakundi PM, Wasunna KM, Rashid JR, Gachihi GS, Mbugua J, Kirigi G, Muttunga J.",Sodium stibogluconate; Allopurinol,Comparative,0,Parasitological,Unspecified,vl,
Kenya (KEN),-1.313005,Spleen,"71",http://www.ncbi.nlm.nih.gov/pubmed/7828501,7828500,-9,Kenya Medical Research institute,65,1994,Allopurinol,Is one year follow-up justified in kala-azar post-treatment?,Eastern Africa,36.803282,Published,"Nyakundi PM, Wasunna KM, Rashid JR, Gachihi GS, Mbugua J, Kirigi G, Muttunga J.",Sodium stibogluconate; Allopurinol,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"137",http://www.ncbi.nlm.nih.gov/pubmed/12792385,12792385,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",39,2003,Miltefosine,Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J.",Miltefosine,Dose finding,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"108",http://www.ncbi.nlm.nih.gov/pubmed/9924534,9924533,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",77,1998,Amphotericin B lipid complex (ABLC),Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.,India Subcontinent,85.400719,Published,"Sundar S, Goyal AK, More DK, Singh MK, Murray HW.",Amphotericin B lipid complex,Dose finding,0,Parasitological,Unspecified,vl,
Brazil (BRA),-20.307558,Bone,"111",http://www.ncbi.nlm.nih.gov/pubmed/7660447,7660446,-9,Hospital Infantil Nossa Senhora da Glória,10,1995,Amphotericin B colloidal dispersion (ABCD),Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.,South America,-40.299789,Published,"Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, Fonschiffrey G, Ksionski G, Dember J.",Amphotericin B dispersion,Single Group,1,Parasitological,Unspecified,vl,
Spain (ESP),37.40599,Bone,"168",http://www.ncbi.nlm.nih.gov/pubmed/11117649,11117648,-9,"Servicio de Enfermedades Infecciosas, Hospital Universitario",32,2000,Meglumine antimoniate,Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy.,Mediterranean,-5.9875722,Published,"Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J.",Meglumine antimoniate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,Unspecified,vl,
Spain (ESP),37.40599,Bone,"168",http://www.ncbi.nlm.nih.gov/pubmed/11117649,11117648,-9,"Servicio de Enfermedades Infecciosas, Hospital Universitario",32,2000,Amphotericin B lipid complex (ABLC),Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy.,Mediterranean,-5.9875722,Published,"Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J.",Meglumine antimoniate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,Unspecified,vl,
Spain (ESP),37.40599,Bone,"168",http://www.ncbi.nlm.nih.gov/pubmed/11117649,11117648,-9,"Servicio de Enfermedades Infecciosas, Hospital Universitario",32,2000,Liposomal Amphotericin B (L-AmB),Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy.,Mediterranean,-5.9875722,Published,"Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J.",Meglumine antimoniate; Liposomal Amphotericin B; Amphotericin B lipid complex,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"116",http://www.ncbi.nlm.nih.gov/pubmed/9851384,9851383,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",30,1998,Miltefosine,Trial of oral miltefosine for visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW.",Miltefosine,Dose finding,0,Parasitological,No,vl,
India (IND),22.575014,Spleen/bone,"212",,,CTRI/2016/08/007190,"School of Tropical Medicine, Calcutta Medical College, Kolkata, India",100,,Miltefosine,Combination chemotherapy against visceral leishmaniasis: Comparative evaluation between miltefosine for 4 weeks and 2 weeks miltefosine combined with single dose liposomal amphotericin B in a tertiary care centre in Kolkata,India Subcontinent,88.359621,Completed,"Rama Prosad Goswami, Sukhen Das",Miltefosine; Liposomal Amphotericin B,Comparative,0,Parasitological,Unspecified,vl,
India (IND),22.575014,Spleen/bone,"212",,,CTRI/2016/08/007190,"School of Tropical Medicine, Calcutta Medical College, Kolkata, India",100,,Liposomal Amphotericin B (L-AmB),Combination chemotherapy against visceral leishmaniasis: Comparative evaluation between miltefosine for 4 weeks and 2 weeks miltefosine combined with single dose liposomal amphotericin B in a tertiary care centre in Kolkata,India Subcontinent,88.359621,Completed,"Rama Prosad Goswami, Sukhen Das",Miltefosine; Liposomal Amphotericin B,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"209",,,CTRI/2017/02/007773,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",564,,Liposomal Amphotericin B (L-AmB),"A Phase III, Open Label, Randomized Trial of Three Single Dose Treatment Regimens of FungisomeTM (Either Alone or in Combination with Miltefosine) Compared with Single Dose Treatment Regimen of AmBisome®, for Visceral Leishmaniasis (VL) in India",India Subcontinent,85.400719,Active,"Shyam Sundar, Krishna Pandey, Rama Prasad Goswami, Lily Verma, Ranjana K Seth",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
Sudan (SDN),13.845118,Spleen/bone/lymph,"63",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Kassab Hospital, Ministry of Health, Gedaref State, Sudan",270,2010,Sodium stibogluconate,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,35.422757,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Kenya"
Sudan (SDN),13.845118,Spleen/bone/lymph,"63",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Kassab Hospital, Ministry of Health, Gedaref State, Sudan",270,2010,Paromomycin,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,35.422757,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Kenya"
Brazil (BRA),-10.181623,Bone/serological,"192",https://www.ncbi.nlm.nih.gov/pubmed/28327805,28327804,-9,"Hospital Dona Regina, Palmas, Tocantins, Brazil",101,2017,Meglumine antimoniate,"Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil",South America,-48.327869,Published,"Myrlena Mescouto Borges, Maria Cristina da Silva Pranchevicius, Elza Ferreira Noronha, Gustavo Adolfo Sierra Romero, César Omar Carranza-Tamayo",Meglumine antimoniate; Amphotericin B deoxycholate,Comparative,1,Mixed,No,vl,
Brazil (BRA),-10.181623,Bone/serological,"192",https://www.ncbi.nlm.nih.gov/pubmed/28327805,28327804,-9,"Hospital Dona Regina, Palmas, Tocantins, Brazil",101,2017,Amphotericin B deoxycholate,"Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil",South America,-48.327869,Published,"Myrlena Mescouto Borges, Maria Cristina da Silva Pranchevicius, Elza Ferreira Noronha, Gustavo Adolfo Sierra Romero, César Omar Carranza-Tamayo",Meglumine antimoniate; Amphotericin B deoxycholate,Comparative,1,Mixed,No,vl,
India (IND),25.274455,Spleen,"14",http://www.ncbi.nlm.nih.gov/pubmed/12456849,12456849,-9,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",398,2002,Miltefosine,Oral miltefosine for Indian visceral leishmaniasis.,India Subcontinent,82.997337,Published,"Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.",Miltefosine,Comparative,0,Parasitological,No,vl,
India (IND),25.274455,Spleen,"14",http://www.ncbi.nlm.nih.gov/pubmed/12456849,12456849,-9,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",398,2002,Amphotericin B deoxycholate,Oral miltefosine for Indian visceral leishmaniasis.,India Subcontinent,82.997337,Published,"Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.",Miltefosine,Comparative,0,Parasitological,No,vl,
Uganda (UGA),1.953632,,"219",,,NCT03129651,"Amudat Hospital, Amudat, Karamoja, Uganda",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,34.943182,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Sudan"
Uganda (UGA),1.953632,,"219",,,NCT03129651,"Amudat Hospital, Amudat, Karamoja, Uganda",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,34.943182,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Sudan"
Uganda (UGA),1.953632,,"219",,,NCT03129651,"Amudat Hospital, Amudat, Karamoja, Uganda",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,34.943182,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Sudan"
Ethiopia (ETH),13.699062,Spleen/bone,"181",https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006989,,NCT02011959,"Abdurafi, Ethiopia",58,2019,Miltefosine,Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients,Eastern Africa,36.468147,Published,"Ermias Diro, Nathalie Strub-Wourgaft, Séverine Blesson",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
Ethiopia (ETH),13.699062,Spleen/bone,"181",https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006989,,NCT02011959,"Abdurafi, Ethiopia",58,2019,Liposomal Amphotericin B (L-AmB),Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients,Eastern Africa,36.468147,Published,"Ermias Diro, Nathalie Strub-Wourgaft, Séverine Blesson",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
India (IND),26.118589,Unknown,"159",http://www.ncbi.nlm.nih.gov/pubmed/24941345,24941345,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",1016,2014,Miltefosine,Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.,India Subcontinent,85.400719,Published,"Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M.",Miltefosine,Single Group,1,Unspecified,Unspecified,vl,Nepal
Sudan (SDN),14.035995,,"218",,,NCT03129650,"Um El Kher Hospital, Um El Kher, Gedaref, Sudan",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.387431,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Sudan (SDN),14.035995,,"218",,,NCT03129650,"Um El Kher Hospital, Um El Kher, Gedaref, Sudan",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.387431,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Sudan (SDN),14.035995,,"218",,,NCT03129650,"Um El Kher Hospital, Um El Kher, Gedaref, Sudan",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.387431,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Kenya (KEN),0.19776,,"231",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Kenya - Site Unknown,3126,2017,Sodium stibogluconate,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,37.396531,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Sudan, Uganda, Ethiopia"
Kenya (KEN),0.19776,,"231",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Kenya - Site Unknown,3126,2017,Paromomycin,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,37.396531,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Sudan, Uganda, Ethiopia"
India (IND),25.620021,Spleen/bone,"97",http://www.ncbi.nlm.nih.gov/pubmed/12955642,12955641,-9,Patna Medical College Hospital,203,2003,Liposomal Amphotericin B (L-AmB),Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.,India Subcontinent,85.159811,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.",Liposomal Amphotericin B,Single Group,1,Parasitological,No,vl,
India (IND),26.118589,,"188",,,CTRI/2009/091/000058,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",,,Liposomal Amphotericin B (L-AmB),"A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul (Amphotericin B Emulsion) As Compared To AmBisome In Patients Of Visceral Leishmaniasis (Kala Azar)",India Subcontinent,85.400719,Completed,Shyam Sundar,Liposomal Amphotericin B,Comparative,1,Mixed,Unspecified,vl,
India (IND),25.620021,Spleen,"39",http://www.ncbi.nlm.nih.gov/pubmed/7979624,7979623,-9,Patna Medical College Hospital,120,1994,Amphotericin B - formulation unknown,Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Barat D, Singh RK.",Amphotericin B,Dose finding,0,Parasitological,Unspecified,vl,
Ethiopia (ETH),12.589413,Spleen/bone/lymph,"90",http://www.ncbi.nlm.nih.gov/pubmed/24454973,24454973, NCT00832211,"Gondar University Hospital, Amhara State, Ethiopia",124,2014,Liposomal Amphotericin B (L-AmB),Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.,Eastern Africa,37.44205,Published,"Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,Sudan
India (IND),26.118589,Spleen,"13",http://www.ncbi.nlm.nih.gov/pubmed/18781879,18781879,NCT00370825,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",226,2008,Miltefosine,New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.,India Subcontinent,85.400719,Published,"Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.",Miltefosine; Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"13",http://www.ncbi.nlm.nih.gov/pubmed/18781879,18781879,NCT00370825,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",226,2008,Liposomal Amphotericin B (L-AmB),New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.,India Subcontinent,85.400719,Published,"Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.",Miltefosine; Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Bangladesh (BGD),23.776417,,"241",,,NCT03636659; CTRI/2018/04/013350,"International Centre for Diarrhoeal Disease Research, Bangladesh",140,,Liposomal Amphotericin B (L-AmB),Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition,India Subcontinent,90.400023,Completed,"Nagesh Meda, Sajid Mohd, Subhra Lahiri, Krishna Pandey, Shyam Sunda, Dinesh Mondal","",Comparative,1,Serological,No,vl,India
Sudan (SDN),13.583108,Spleen/bone/lymph,"102",http://www.ncbi.nlm.nih.gov/pubmed/22724031,22724031,NCT00255569,"Um el Kheir Treatment Center, Gedaref State, Sudan",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,35.087274,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Kenya"
Sudan (SDN),13.583108,Spleen/bone/lymph,"102",http://www.ncbi.nlm.nih.gov/pubmed/22724031,22724031,NCT00255569,"Um el Kheir Treatment Center, Gedaref State, Sudan",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,35.087274,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Ethiopia, Kenya"
India (IND),25.613897,Spleen/bone,"45",http://www.ncbi.nlm.nih.gov/pubmed/18765879,18765878,-9,"Balaji Uthan Sansthan, Patna, India",140,2008,Sodium stibogluconate,Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.,India Subcontinent,85.139591,Published,"Thakur CP, Thakur S, Narayan S, Sinha A.",Sodium stibogluconate,Comparative,0,Parasitological,Unspecified,vl,
Sudan (SDN),15.502795,Spleen/bone/lymph,"107",http://www.ncbi.nlm.nih.gov/pubmed/8236403,8236402,-9,"Kala-azar Hospital, El-Gerief-West",104,1993,Sodium stibogluconate,The treatment of kala-azar in the Sudan with sodium stibogluconate: a randomized trial of three dosage regimens.,Eastern Africa,32.519441,Published,"Zijlstra EE, Siddig Ali M, el-Hassan AM, Hofland HW, el-Toum I, Satti M, Ghalib HW.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"174",http://www.ncbi.nlm.nih.gov/pubmed/25233347,25233347, NCT00876825,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",500,2014,Amphotericin B lipid emulsion (ABLE),"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.",India Subcontinent,85.400719,Published,"Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P.",Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"174",http://www.ncbi.nlm.nih.gov/pubmed/25233347,25233347, NCT00876825,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",500,2014,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.",India Subcontinent,85.400719,Published,"Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P.",Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen,"12",http://www.ncbi.nlm.nih.gov/pubmed/10588964,10588964,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",120,1999,Miltefosine,"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.",India Subcontinent,85.400719,Published,"Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J.",Miltefosine,Dose finding,0,Parasitological,No,vl,
India (IND),26.131728,Spleen/bone,"75",http://www.ncbi.nlm.nih.gov/pubmed/12135285,12135284,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",84,2002,Liposomal Amphotericin B (L-AmB),Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.,India Subcontinent,85.896955,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,
India (IND),26.131728,Spleen,"154",http://www.ncbi.nlm.nih.gov/pubmed/7883661,7883660,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",100,1994,Amphotericin B deoxycholate,Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.,India Subcontinent,85.896955,Published,"Giri OP, Singh AN.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
Sudan (SDN),13.511629,Spleen/bone/lymph,"195",https://www.ncbi.nlm.nih.gov/pubmed/27627657,27627657,NCT010667446,"El Hassan Centre for Tropical Medicine, Doka,Sudan",183,2016,Sodium stibogluconate,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.740262,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
Sudan (SDN),13.511629,Spleen/bone/lymph,"195",https://www.ncbi.nlm.nih.gov/pubmed/27627657,27627657,NCT010667446,"El Hassan Centre for Tropical Medicine, Doka,Sudan",183,2016,Miltefosine,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.740262,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
Sudan (SDN),13.511629,Spleen/bone/lymph,"195",https://www.ncbi.nlm.nih.gov/pubmed/27627657,27627657,NCT010667446,"El Hassan Centre for Tropical Medicine, Doka,Sudan",183,2016,Liposomal Amphotericin B (L-AmB),Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.740262,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Kenya
Brazil (BRA),-19.924993,Bone,"204",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Pediatric Hospital Joao Paulo II—FHEMIG, Belo Horizonte",378,2017,Meglumine antimoniate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.931761,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-19.924993,Bone,"204",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Pediatric Hospital Joao Paulo II—FHEMIG, Belo Horizonte",378,2017,Amphotericin B deoxycholate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.931761,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-19.924993,Bone,"204",https://www.ncbi.nlm.nih.gov/pubmed/28662038,28662038,NCT01310742,"Pediatric Hospital Joao Paulo II—FHEMIG, Belo Horizonte",378,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-43.931761,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
India (IND),25.599832,Spleen/bone,"224",https://www.ncbi.nlm.nih.gov/pubmed/29016288,29016288,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",100,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India",India Subcontinent,85.195326,Published,"Pandey K, Pal B, Siddiqui NA, Rabi Das VN, Murti K, Lal CS, Verma N, Babu R, Ali V, Kumar R, Das P",Liposomal Amphotericin B,Single Group,0,Parasitological,No,vl,
Italy (ITA),44.391586,Spleen/bone,"72",http://www.ncbi.nlm.nih.gov/pubmed/8153292,8153291,-9,G. Gaslini Children’s Hospital,31,1994,Liposomal Amphotericin B (L-AmB),Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.,Mediterranean,8.9861786,Published,"Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, Pempinello R, Scott S, Raimondi F, Cascio A, et al.",Liposomal Amphotericin B,Dose finding,0,Parasitological,Yes,vl,
India (IND),26.131728,Spleen/bone,"99",http://www.ncbi.nlm.nih.gov/pubmed/12955642,12955641,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",203,2003,Liposomal Amphotericin B (L-AmB),Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.,India Subcontinent,85.896955,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.",Liposomal Amphotericin B,Single Group,1,Parasitological,No,vl,
Spain (ESP),40.475901,Spleen/bone/liver,"20",http://www.ncbi.nlm.nih.gov/pubmed/10397536,10397536,-9,"Servicio de Enfermedades Infecciosas, Centro Nacional de Investigación Clínica, Instituto de Salud Carlos III, Madrid, Spain",89,1999,Meglumine antimoniate,Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.,Mediterranean,-3.694681,Published,"Laguna F, López-Vélez  R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G,Gómez-Rodrigo J, Pasquau J, Alvar J.",Amphotericin B; Meglumine antimoniate,Comparative,0,Parasitological,Yes,vl,
Spain (ESP),40.475901,Spleen/bone/liver,"20",http://www.ncbi.nlm.nih.gov/pubmed/10397536,10397536,-9,"Servicio de Enfermedades Infecciosas, Centro Nacional de Investigación Clínica, Instituto de Salud Carlos III, Madrid, Spain",89,1999,Amphotericin B deoxycholate,Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.,Mediterranean,-3.694681,Published,"Laguna F, López-Vélez  R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G,Gómez-Rodrigo J, Pasquau J, Alvar J.",Amphotericin B; Meglumine antimoniate,Comparative,0,Parasitological,Yes,vl,
India (IND),28.6448,,"262",https://pubmed.ncbi.nlm.nih.gov/17642948/,17642948,,India - site unknown,10,2003,Ketoconazole,Therapeutic trial of sodium antimony gluconate alone and in combination with ketoconazole in post-kala-azar dermal leishmaniasis.,India Subcontinent,77.216721,Published,"S K Rathi, R K Pandhi, N Khanna, P Chopra ","",RCT,0,Mixed,Unspecified,pkdl,
India (IND),28.6448,,"262",https://pubmed.ncbi.nlm.nih.gov/17642948/,17642948,,India - site unknown,10,2003,Sodium stibogluconate,Therapeutic trial of sodium antimony gluconate alone and in combination with ketoconazole in post-kala-azar dermal leishmaniasis.,India Subcontinent,77.216721,Published,"S K Rathi, R K Pandhi, N Khanna, P Chopra ","",RCT,0,Mixed,Unspecified,pkdl,
India (IND),25.613897,Unspecified,"220",,,CTRI/2017/05/008656,"Balaji Uthan Sansthan, Patna, India",130,,Amphotericin B," A multicenter, open label, randomized, two treatment, parallel design, steady state study to compare the bioavailability of the Test product [Amphotericin B (Liposome for injection) 50 mg/vial, Cipla Ltd., India] with Reference product [AmBisomeÂ® (Amphotericin B) Liposome for injection 50 mg/vial), Gilead life sciences, USA] in adult patients with visceral leishmaniasis.",India Subcontinent,85.139591,Active,"CP Thakur, Rama Prasad Goswami,  Shyam Sundar, Krishna Pandey",Liposomal Amphotericin B,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.121473,,"258",https://pubmed.ncbi.nlm.nih.gov/25685839/,25685839,,"Kala-Azar Medical Research Center, Muzaffarpur, India",33,2015,Miltefosine,Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ,India Subcontinent,85.368752,Published,"Shyam Sundar, Anup Singh, Jaya Chakravarty, Madhukar Rai","",Single-arm trial,0,Mixed,No,pkdl,
Kenya (KEN),1.497147,,"216",,,NCT03129648,"Kacheliba Hospital, Kacheliba, West Pokot, Kenya",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.005334,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
Kenya (KEN),1.497147,,"216",,,NCT03129648,"Kacheliba Hospital, Kacheliba, West Pokot, Kenya",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.005334,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
Kenya (KEN),1.497147,,"216",,,NCT03129648,"Kacheliba Hospital, Kacheliba, West Pokot, Kenya",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.005334,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Sudan, Uganda"
India (IND),25.620021,Unknown,"170",http://www.ncbi.nlm.nih.gov/pubmed/9654264,9654264,-9,Patna Medical College Hospital,75,1998,Amphotericin B,"Sodium antimony gluconate, amphotericin, and myocardial damage.",India Subcontinent,85.159811,Published,Thakur CP.,Amphotericin B,Single Group,0,Unspecified,Unspecified,vl,
Brazil (BRA),-16.730747,Bone/serological,"191",https://www.ncbi.nlm.nih.gov/pubmed/28327805,28327804,-9,"Hospital de Doenças Tropicais, Araguaína, Tocantins, Brazil",101,2017,Meglumine antimoniate,"Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil",South America,-49.23737,Published,"Myrlena Mescouto Borges, Maria Cristina da Silva Pranchevicius, Elza Ferreira Noronha, Gustavo Adolfo Sierra Romero, César Omar Carranza-Tamayo",Meglumine antimoniate; Amphotericin B deoxycholate,Comparative,1,Mixed,No,vl,
Brazil (BRA),-16.730747,Bone/serological,"191",https://www.ncbi.nlm.nih.gov/pubmed/28327805,28327804,-9,"Hospital de Doenças Tropicais, Araguaína, Tocantins, Brazil",101,2017,Amphotericin B deoxycholate,"Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil",South America,-49.23737,Published,"Myrlena Mescouto Borges, Maria Cristina da Silva Pranchevicius, Elza Ferreira Noronha, Gustavo Adolfo Sierra Romero, César Omar Carranza-Tamayo",Meglumine antimoniate; Amphotericin B deoxycholate,Comparative,1,Mixed,No,vl,
Iran (Islamic Republic of) (IRN),29.629926,Spleen/bone/serological,"138",http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/219/CN-00664219/frame.html,-1,-9,Shiraz University of Medical Sciences,75,1998,Meglumine antimoniate,Short course anti-leishmania therapy in children with visceral leishmaniasis .,Central Asia,52.521502,Published,"Karimi A, Alborzi I, Mahmodi MR, Rakhshani AH, Kadivar MR",Meglumine antimoniate,Dose finding,0,Mixed,Unspecified,vl,
Ethiopia (ETH),12.616184,,"214",,,NCT03129646,"University Hospital of Gondar, Gondar, Ethiopia",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,37.454676,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Kenya, Sudan, Uganda"
Ethiopia (ETH),12.616184,,"214",,,NCT03129646,"University Hospital of Gondar, Gondar, Ethiopia",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,37.454676,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Kenya, Sudan, Uganda"
Ethiopia (ETH),12.616184,,"214",,,NCT03129646,"University Hospital of Gondar, Gondar, Ethiopia",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,37.454676,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Kenya, Sudan, Uganda"
Brazil (BRA),-13.00246,Spleen/bone,"53",http://www.ncbi.nlm.nih.gov/pubmed/11105144,11105143,-9,"Federal University of Bahia,Brazil",32,1997,Liposomal Amphotericin B (L-AmB),Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil.,South America,-38.511164,Published,"Freire M, Badaró F, Avelar ME, Luz K, Nakatani MS, Teixeira R, Martins Netto E, Badaró R.",Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
India (IND),25.613897,Spleen,"50",http://www.ncbi.nlm.nih.gov/pubmed/9797830,9797829,-9,"Balaji Uthan Sansthan, Patna, India",80,1998,Sodium stibogluconate,"Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.",India Subcontinent,85.139591,Published,"Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK.",Sodium stibogluconate,Single Group,1,Parasitological,No,vl,
India (IND),26.121473,,"257",https://pubmed.ncbi.nlm.nih.gov/23136856/,23136856,,"Kala-Azar Medical Research Center, Muzaffarpur, India; Rajendra Memorial Research Institute of Medical Sciences, Patna, India; Institute of Medical Sciences, Banaras Hindu University, Varanasi, India",36,2013,Miltefosine,Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. ,India Subcontinent,85.368752,Published,"Shyam Sundar, Prabat Sinha, T K Jha, Jaya Chakravarty, Madhukar Rai, Nawin Kumar, Krishna Pandey, M K Narain, N Verma, V N R Das, P Das, Jonathan Berman, Byron Arana ","",RCT,0,Mixed,No,pkdl,
India (IND),25.613897,Spleen,"31",http://www.ncbi.nlm.nih.gov/pubmed/16354803,16354802,-9,"Balaji Uthan Sansthan, Patna, India",120,2005,Sitamaquine,A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.,India Subcontinent,85.139591,Published,"Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J.",Sitamaquine,Dose finding,0,Parasitological,No,vl,
Sudan (SDN),13.845118,Bone,"79",http://www.ncbi.nlm.nih.gov/pubmed/21049065,21049065,NCT00255569,"Kassab Hospital, Ministry of Health, Gedaref State",42,2010,Paromomycin sulphate,"Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.",Eastern Africa,35.422757,Published,"Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E.",Paromomycin,Dose finding,0,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"60",http://www.ncbi.nlm.nih.gov/pubmed/11049799,11049798,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",320,2000,Sodium stibogluconate,Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.,India Subcontinent,85.400719,Published,"Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW.",Sodium stibogluconate,Single Group,1,Parasitological,Unspecified,vl,
Sudan (SDN),9.6655153,Spleen/lymph,"73",http://www.ncbi.nlm.nih.gov/pubmed/7578730,7578729,-9,"Western Upper Nile, Sudan",49,1995,Liposomal Amphotericin B (L-AmB),Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions.,Eastern Africa,28.873127,Published,"Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R.",Liposomal Amphotericin B,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),22.575014,Unspecified,"221",,,CTRI/2017/05/008656,"Calcutta School of Tropical Medicine, Calcutta",130,,Amphotericin B," A multicenter, open label, randomized, two treatment, parallel design, steady state study to compare the bioavailability of the Test product [Amphotericin B (Liposome for injection) 50 mg/vial, Cipla Ltd., India] with Reference product [AmBisomeÂ® (Amphotericin B) Liposome for injection 50 mg/vial), Gilead life sciences, USA] in adult patients with visceral leishmaniasis.",India Subcontinent,88.359621,Active,"CP Thakur, Rama Prasad Goswami,  Shyam Sundar, Krishna Pandey",Liposomal Amphotericin B,Comparative,0,Unspecified,Unspecified,vl,
India (IND),22.575014,Spleen/bone,"9",http://www.ncbi.nlm.nih.gov/pubmed/9282505,9282505,-9,"Calcutta School of Tropical Medicine, Calcutta",180,1997,Ketoconazole,Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar--a comparative study.,India Subcontinent,88.359621,Published,"Wali JP, Aggarwal P, Nandy A, Singh S, Addy M, Guha SK, Dwivedi SN, Karmarkar MG, Maji AK.",Ketoconazole; Sodium stibogluconate,Comparative,1,Parasitological,Unspecified,vl,
India (IND),22.575014,Spleen/bone,"9",http://www.ncbi.nlm.nih.gov/pubmed/9282505,9282505,-9,"Calcutta School of Tropical Medicine, Calcutta",180,1997,Sodium stibogluconate,Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar--a comparative study.,India Subcontinent,88.359621,Published,"Wali JP, Aggarwal P, Nandy A, Singh S, Addy M, Guha SK, Dwivedi SN, Karmarkar MG, Maji AK.",Ketoconazole; Sodium stibogluconate,Comparative,1,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen/bone,"5",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",634,2011,Miltefosine,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.195326,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),25.599832,Spleen/bone,"5",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",634,2011,Amphotericin B deoxycholate,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.195326,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),25.599832,Spleen/bone,"5",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",634,2011,Liposomal Amphotericin B (L-AmB),"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.195326,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),25.599832,Spleen/bone,"5",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",634,2011,Paromomycin,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.195326,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
Ethiopia (ETH),6.0284459,Spleen/bone/lymph,"62",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Arba Minch Hospital, SNNPR State, Ethiopia",270,2010,Sodium stibogluconate,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,37.550195,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Kenya"
Ethiopia (ETH),6.0284459,Spleen/bone/lymph,"62",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Arba Minch Hospital, SNNPR State, Ethiopia",270,2010,Paromomycin,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,37.550195,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Sudan, Kenya"
India (IND),26.118589,Spleen/bone,"6",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",634,2011,Miltefosine,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"6",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",634,2011,Amphotericin B deoxycholate,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"6",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",634,2011,Liposomal Amphotericin B (L-AmB),"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"6",http://www.ncbi.nlm.nih.gov/pubmed/21255828,21255828,NCT00696969,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",634,2011,Paromomycin,"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.",Miltefosine; Amphotericin B deoxycholate; Paromomycin; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,
Brazil (BRA),-3.744739,Unspecified,"250",,,,"Hospital São José de Doenças Infecciosas, Fortaleza, Brazil",17,,Liposomal Amphotericin B (L-AmB),,South America,-38.558288,Not Published,,"",Single Group,0,Unspecified,Unspecified,vl,
Ethiopia (ETH),8.9825468,Spleen/bone/lymph,"11",http://www.ncbi.nlm.nih.gov/pubmed/10513651,10513651,-1,"Institute of Pathobiology, Addis Ababa University, Ethiopia",23,1999,Sodium stibogluconate,HIV viral load and response to antileishmanial chemotherapy in co-infected patients.,Eastern Africa,38.751128,Published,"Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-Michael T, Desjeux P, SÃ¶nnerborg A, Akuffo H, Britton S.",Sodium stibogluconate,Single Group,0,Parasitological,Yes,vl,
India (IND),25.599832,Spleen/bone,"210",,,CTRI/2017/02/007773,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",564,,Liposomal Amphotericin B (L-AmB),"A Phase III, Open Label, Randomized Trial of Three Single Dose Treatment Regimens of FungisomeTM (Either Alone or in Combination with Miltefosine) Compared with Single Dose Treatment Regimen of AmBisome®, for Visceral Leishmaniasis (VL) in India",India Subcontinent,85.195326,Active,"Shyam Sundar, Krishna Pandey, Rama Prasad Goswami, Lily Verma, Ranjana K Seth",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
Sudan (SDN),15.65,,"254",https://pubmed.ncbi.nlm.nih.gov/17963805/,17963805,,"Tropical Diseases Hospital, Omdurman, Sudan",30,2008,Sodium stibogluconate,Leishmaniasis Research Group/Sudan. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. ,Eastern Africa,32.483334,Published,"Ahmed Mudawi Musa, Eltahir Awad Khalil, Fawzi Abd Mahgoub, Sara Hamad Elgawi, Farroukh Modabber, Abd Elgadir Mohamed Yousif Elkadaru, Mona Hussein Aboud, Sassan Noazin, Hashim Warsama Ghalib, Ahmed Mohammed El-Hassan","",RCT,0,Mixed,No,pkdl,
India (IND),26.118589,Spleen,"34",http://www.ncbi.nlm.nih.gov/pubmed/16447105,16447104,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",405,2006,Amphotericin B colloidal dispersion (ABCD),Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M.",Amphotericin B dispersion,Dose finding,0,Parasitological,No,vl,
India (IND),26.131728,Bone,"129",http://www.ncbi.nlm.nih.gov/pubmed/3935210,3935209,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",10,1985,Metronidazole,Metronidazole and Indian kala-azar: results of a clinical trial.,India Subcontinent,85.896955,Published,"Mishra M, Thakur BD, Choudhary M.",Metronidazole,Single Group,0,Parasitological,Unspecified,vl,
Italy (ITA),40.86675,Bone,"10",http://www.ncbi.nlm.nih.gov/pubmed/11200380,11200380,-9,"Dipartimento di Malattie Infettive, Seconda Università, Naples",12,2000,Amphotericin B colloidal dispersion (ABCD),Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients.,Mediterranean,14.217966,Published,"Gaeta GB, Maisto A, Di Caprio D, Scalone A, Pasquale G, Felaco FM, Galante D, Gradoni L.",Amphotericin B dispersion,Single Group,0,Parasitological,No,vl,
India (IND),22.572645,,"259",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596597/,26175030,,"School of Tropical Medicine, Kolkata, India; Institute of Postgraduate Medical Education and Research, Kolkata, India",27,2015,Miltefosine, Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis. ,India Subcontinent,88.363892,Published,"Susmita Ghosh, Nilay Kanti Das, Shibabrata Mukherjee, Debanjan Mukhopadhyay, Jayashree Nath Barbhuiya, Avijit Hazra, Mitali Chatterjee","",Single-arm trial,0,Mixed,Unspecified,pkdl,
Iran (Islamic Republic of) (IRN),29.629926,Bone/serological,"213",https://www.ncbi.nlm.nih.gov/pubmed/27879461,27879460,-9,Shiraz University of Medical Sciences,75,2017,Meglumine antimoniate,"Effectiveness of Short-Course Meglumine Antimoniate (Glucantime�) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran",Central Asia,52.521502,Published,"Abdolvahab Alborzi, Gholamreza Pouladfar, Armin Attar, Fatemeh Falahi, Zahra Jafarpour, Abdollah Karimi, Mohammad Rahim Kadivar",Meglumine antimoniate,Dose finding,0,Mixed,Unspecified,vl,
Ethiopia (ETH),12.589413,Spleen/bone,"180",https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006989,,NCT02011959,"Gondar University Hospital, Amhara State, Ethiopia",58,2019,Miltefosine,Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients,Eastern Africa,37.44205,Published,"Ermias Diro, Nathalie Strub-Wourgaft, Séverine Blesson",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
Ethiopia (ETH),12.589413,Spleen/bone,"180",https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006989,,NCT02011959,"Gondar University Hospital, Amhara State, Ethiopia",58,2019,Liposomal Amphotericin B (L-AmB),Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients,Eastern Africa,37.44205,Published,"Ermias Diro, Nathalie Strub-Wourgaft, Séverine Blesson",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
India (IND),25.602357,Spleen,"136",http://www.ncbi.nlm.nih.gov/pubmed/17202634,17202633,-9,Nalanda Medical College,125,2006,Miltefosine,"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.",India Subcontinent,85.197018,Published,"Singh UK, Prasad R, Mishra OP, Jayswal BP.",Miltefosine; Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),25.602357,Spleen,"136",http://www.ncbi.nlm.nih.gov/pubmed/17202634,17202633,-9,Nalanda Medical College,125,2006,Amphotericin B - formulation unknown,"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.",India Subcontinent,85.197018,Published,"Singh UK, Prasad R, Mishra OP, Jayswal BP.",Miltefosine; Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"128",http://www.ncbi.nlm.nih.gov/pubmed/8406645,8406644,-9,Patna Medical College Hospital,150,1993,Sodium stibogluconate,Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"128",http://www.ncbi.nlm.nih.gov/pubmed/8406645,8406644,-9,Patna Medical College Hospital,150,1993,Amphotericin B deoxycholate,Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"133",http://www.ncbi.nlm.nih.gov/pubmed/8244484,8244483,-9,Patna Medical College Hospital,50,1993,Amphotericin B deoxycholate,Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Sharma V, Pandey AK, Sinha PK, Barat D.",Amphotericin B,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.599832,Spleen,"134",http://www.ncbi.nlm.nih.gov/pubmed/14699453,14699453,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",80,2004,Miltefosine,Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.,India Subcontinent,85.195326,Published,"Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD.",Miltefosine,Single Group,0,Parasitological,No,vl,
Kenya (KEN),0.463834,Spleen/bone/lymph,"194",https://www.ncbi.nlm.nih.gov/pubmed/27627656,27627656,NCT010667445,"Kimalel Health Center, Kenya ",183,2016,Sodium stibogluconate,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.892251,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Sudan
Kenya (KEN),0.463834,Spleen/bone/lymph,"194",https://www.ncbi.nlm.nih.gov/pubmed/27627656,27627656,NCT010667445,"Kimalel Health Center, Kenya ",183,2016,Miltefosine,Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.892251,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Sudan
Kenya (KEN),0.463834,Spleen/bone/lymph,"194",https://www.ncbi.nlm.nih.gov/pubmed/27627656,27627656,NCT010667445,"Kimalel Health Center, Kenya ",183,2016,Liposomal Amphotericin B (L-AmB),Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial,Eastern Africa,35.892251,Published,"Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P. C. Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E. Kip, Gerard J. Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa",Miltefosine; Sodium stibogluconate; Liposomal Amphotericin B,Comparative,1,Parasitological,No,vl,Sudan
Sudan (SDN),13.511629,,"217",,,NCT03129649,"El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan",576,,Miltefosine,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.740262,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Sudan (SDN),13.511629,,"217",,,NCT03129649,"El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan",576,,Sodium stibogluconate,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.740262,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Sudan (SDN),13.511629,,"217",,,NCT03129649,"El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan",576,,Paromomycin,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,Eastern Africa,35.740262,Active,"Jane Mbui,  Joseph Olobo,  Ahmed M Musa, Rezika Mohammed",Miltefosine; Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,No,vl,"Ethiopia, Kenya, Uganda"
Ethiopia (ETH),14.285302,Spleen/lymph/serological,"1",http://www.ncbi.nlm.nih.gov/pubmed/16804852,16804852,-9,Humera hospital,580,2006,Miltefosine,A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.,Eastern Africa,36.611923,Published,"Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.",Miltefosine; Sodium stibogluconate,Comparative,0,Mixed,Yes,vl,
Ethiopia (ETH),14.285302,Spleen/lymph/serological,"1",http://www.ncbi.nlm.nih.gov/pubmed/16804852,16804852,-9,Humera hospital,580,2006,Sodium stibogluconate,A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.,Eastern Africa,36.611923,Published,"Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.",Miltefosine; Sodium stibogluconate,Comparative,0,Mixed,Yes,vl,
Brazil (BRA),-5.058105,Bone,"202",https://www.ncbi.nlm.nih.gov/pubmed/28662036,28662036,NCT01310740,"Federal University of Piauí, Teresina",378,2017,Meglumine antimoniate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-42.798262,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-5.058105,Bone,"202",https://www.ncbi.nlm.nih.gov/pubmed/28662036,28662036,NCT01310740,"Federal University of Piauí, Teresina",378,2017,Amphotericin B deoxycholate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-42.798262,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-5.058105,Bone,"202",https://www.ncbi.nlm.nih.gov/pubmed/28662036,28662036,NCT01310740,"Federal University of Piauí, Teresina",378,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-42.798262,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Sudan (SDN),15.689141,,"229",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Sudan - Site Unknown,3126,2017,Sodium stibogluconate,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,29.765189,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Ethiopia, Kenya, Uganda"
Sudan (SDN),15.689141,,"229",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Sudan - Site Unknown,3126,2017,Paromomycin,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,29.765189,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Ethiopia, Kenya, Uganda"
India (IND),26.118589,Spleen/bone,"85",http://www.ncbi.nlm.nih.gov/pubmed/9583928,9583927,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",120,1998,Sodium stibogluconate,"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.",India Subcontinent,85.400719,Published,"Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"85",http://www.ncbi.nlm.nih.gov/pubmed/9583928,9583927,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",120,1998,Paromomycin,"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.",India Subcontinent,85.400719,Published,"Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,No,vl,
Brazil (BRA),-12.993413,,"207",,,NCT01138956,"Hospital Universitário Professor Edgard Santos, Brazil",40,,n-acetylcysteine,Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine,South America,-38.522392,Unknown,"Roque P Almeida, Enaldo V Melo, Angela M Silva",Pentavalent Antimonial; N-acetylcysteine,Comparative,0,Unspecified,Unspecified,vl,
Brazil (BRA),-12.993413,,"207",,,NCT01138956,"Hospital Universitário Professor Edgard Santos, Brazil",40,,Pentavalent antimonial,Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine,South America,-38.522392,Unknown,"Roque P Almeida, Enaldo V Melo, Angela M Silva",Pentavalent Antimonial; N-acetylcysteine,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.118589,Spleen,"164",http://www.ncbi.nlm.nih.gov/pubmed/21609983,21609983,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",46,2011,Amphotericin B lipid emulsion (ABLE),Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sudarshan M, Weirather JL, Wilson ME, Sundar S.",Amphotericin B; Amphotericin B lipid emulsion,Single Group,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"164",http://www.ncbi.nlm.nih.gov/pubmed/21609983,21609983,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",46,2011,Liposomal Amphotericin B (L-AmB),Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis.,India Subcontinent,85.400719,Published,"Sudarshan M, Weirather JL, Wilson ME, Sundar S.",Amphotericin B; Amphotericin B lipid emulsion,Single Group,0,Parasitological,No,vl,
India (IND),25.612677,,"260",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1247932/,2823955,,"Patna Medical College and Hospital, Patna, India",108,1987,Sodium stibogluconate,Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. ,India Subcontinent,85.158875,Published," C P Thakur, K Kumar, P K Sinha, B N Mishra, A K Pandey ","",RCT,0,Mixed,Unspecified,pkdl,
India (IND),25.599832,Spleen/bone,"27",http://www.ncbi.nlm.nih.gov/pubmed/19436614,19436614,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",82,2009,Amphotericin B deoxycholate,"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.",India Subcontinent,85.195326,Published,"Das VN, Siddiqui NA, Pandey K, Singh VP, Topno RK, Singh D, Verma RB, Ranjan A, Sinha PK, Das P.",Amphotericin B deoxycholate; Pentamidine,Comparative,0,Parasitological,No,vl,
India (IND),25.599832,Spleen/bone,"27",http://www.ncbi.nlm.nih.gov/pubmed/19436614,19436614,-9,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",82,2009,Pentamidine,"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.",India Subcontinent,85.195326,Published,"Das VN, Siddiqui NA, Pandey K, Singh VP, Topno RK, Singh D, Verma RB, Ranjan A, Sinha PK, Das P.",Amphotericin B deoxycholate; Pentamidine,Comparative,0,Parasitological,No,vl,
India (IND),25.612677,,"253",https://pubmed.ncbi.nlm.nih.gov/33580944/,33580944,CTRI/2018/05/014015,"Rajendra Memorial Research Institute of Medical Sciences, Patna, India",100,2021,Miltefosine,"A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.",India Subcontinent,85.158875,Published,"Krishna Pandey, Biplab Pal, Niyamat Ali Siddiqui, Chandra Shekhar Lal, Vahab Ali, Sanjiva Bimal, Ashish Kumar, Neena Verma, Vidya Nand Rabi Das, Shubhankar Kumar Singh, Roshan Kamal Topno, Pradeep Das ","",RCT,0,Mixed,No,pkdl,
India (IND),25.612677,,"253",https://pubmed.ncbi.nlm.nih.gov/33580944/,33580944,CTRI/2018/05/014015,"Rajendra Memorial Research Institute of Medical Sciences, Patna, India",100,2021,Liposomal Amphotericin B (L-AmB),"A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.",India Subcontinent,85.158875,Published,"Krishna Pandey, Biplab Pal, Niyamat Ali Siddiqui, Chandra Shekhar Lal, Vahab Ali, Sanjiva Bimal, Ashish Kumar, Neena Verma, Vidya Nand Rabi Das, Shubhankar Kumar Singh, Roshan Kamal Topno, Pradeep Das ","",RCT,0,Mixed,No,pkdl,
Nepal (NPL),26.80877,Spleen/bone,"68",http://www.ncbi.nlm.nih.gov/pubmed/23425959,23425958,-9,"B. P. Koirala Institute of Health Sciences (BPKIHS),",120,2013,Miltefosine,"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.",India Subcontinent,87.262131,Published,"Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC.",Miltefosine,Single Group,0,Parasitological,Yes,vl,
India (IND),26.166981,Spleen/bone,"152",http://www.ncbi.nlm.nih.gov/pubmed/1938818,1938817,-1,S.K Medical College Hospital,240,1991,Pentamidine isethionate,Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.,India Subcontinent,85.391184,Published,"Jha SN, Singh NK, Jha TK.",Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.166981,Spleen/bone,"152",http://www.ncbi.nlm.nih.gov/pubmed/1938818,1938817,-1,S.K Medical College Hospital,240,1991,Pentamidine,Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.,India Subcontinent,85.391184,Published,"Jha SN, Singh NK, Jha TK.",Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
Bangladesh (BGD),24.704209,Spleen/bone,"198",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558065, NCT01122774,"Community Based Medical College, Trishal,Mymensingh, Bangladesh",602,2017,Miltefosine,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.388805,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.704209,Spleen/bone,"198",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558065, NCT01122774,"Community Based Medical College, Trishal,Mymensingh, Bangladesh",602,2017,Liposomal Amphotericin B (L-AmB),"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.388805,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
Bangladesh (BGD),24.704209,Spleen/bone,"198",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466346/,28558065, NCT01122774,"Community Based Medical College, Trishal,Mymensingh, Bangladesh",602,2017,Paromomycin,"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh",India Subcontinent,90.388805,Published,"Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.",Miltefosine; Paromomycin; Liposomal Amphotericin B,Comparative,1,Mixed,No,vl,
India (IND),26.121473,,"256",https://pubmed.ncbi.nlm.nih.gov/27398387/,27398387,,"Kala-Azar Medical Research Center, Muzaffarpur, India",31,2014,Paromomycin,Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis.,India Subcontinent,85.368752,Published,"Shyam Sundar, Anup Singh, Anurag Tiwari, Saurabh Shukla, Jaya Chakravarty, Madhukar Rai ","",Single-arm trial,0,Mixed,No,pkdl,
India (IND),28.6448,,"261",https://pubmed.ncbi.nlm.nih.gov/21561437/,21561437,,"Safdarjung Hospital Campus, New Delhi, India",26,2011,Miltefosine,Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. ,India Subcontinent,77.216721,Published,"V Ramesh, G K Katara, S Verma, P Salotra","",Single-arm trial,0,Mixed,No,pkdl,
India (IND),25.996603,,"228",https://www.ncbi.nlm.nih.gov/pubmed/27645786,27645786,-9,Primary health centre in Baniyapur of Saran District of Bihar,646,2016,Miltefosine,"Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India",India Subcontinent,84.69031,Published,"Krishna Pandey, Vidyanand Ravidas, Niyamat A. Siddiqui, Sanjay K. Sinha, Rakesh B. Verma, Tripurari P. Singh, A. C. Dhariwal, R. K. Das Gupta, and Pradeep Das","",Single Group,1,Parasitological,No,vl,
India (IND),25.613271,Spleen/bone,"115",https://www.ncbi.nlm.nih.gov/pubmed/1337635,1337634,-9,Tripolia social service hospital,24,1992,Sodium stibogluconate,"Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.",India Subcontinent,85.18754,Published,"Thakur CP, Olliaro P, Gothoskar S, Bhowmick S, Choudhury BK, Prasad S, Kumar M, Verma BB.",Sodium stibogluconate; Paromomycin,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.613271,Spleen/bone,"115",https://www.ncbi.nlm.nih.gov/pubmed/1337635,1337634,-9,Tripolia social service hospital,24,1992,Paromomycin,"Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.",India Subcontinent,85.18754,Published,"Thakur CP, Olliaro P, Gothoskar S, Bhowmick S, Choudhury BK, Prasad S, Kumar M, Verma BB.",Sodium stibogluconate; Paromomycin,Single Group,0,Parasitological,Unspecified,vl,
Nepal (NPL),26.80877,,"186",,,ACTRN12610000130066,"B. P. Koirala Institute of Health Sciences (BPKIHS),",35,,Liposomal Amphotericin B (L-AmB),Liposomal amphotericin B for the treatment of Nepalese patients with visceral leishmaniasis,India Subcontinent,87.262131,Completed,Suman Rijal,Liposomal Amphotericin B,Single Group,0,Mixed,Unspecified,vl,
India (IND),22.575014,Spleen/bone,"211",,,CTRI/2017/02/007773,"School of Tropical Medicine, Calcutta Medical College, Kolkata, India",564,,Liposomal Amphotericin B (L-AmB),"A Phase III, Open Label, Randomized Trial of Three Single Dose Treatment Regimens of FungisomeTM (Either Alone or in Combination with Miltefosine) Compared with Single Dose Treatment Regimen of AmBisome®, for Visceral Leishmaniasis (VL) in India",India Subcontinent,88.359621,Active,"Shyam Sundar, Krishna Pandey, Rama Prasad Goswami, Lily Verma, Ranjana K Seth",Miltefosine; Liposomal Amphotericin B,Comparative,1,Parasitological,Unspecified,vl,
India (IND),26.087327,,"227",https://www.ncbi.nlm.nih.gov/pubmed/27645786,27645786,-9,Primary health centre in Paroo of Muzaffarpur,646,2016,Miltefosine,"Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India",India Subcontinent,85.062969,Published,"Krishna Pandey, Vidyanand Ravidas, Niyamat A. Siddiqui, Sanjay K. Sinha, Rakesh B. Verma, Tripurari P. Singh, A. C. Dhariwal, R. K. Das Gupta, and Pradeep Das","",Single Group,1,Parasitological,No,vl,
India (IND),26.118589,Spleen,"96",http://www.ncbi.nlm.nih.gov/pubmed/9230004,9230003,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",60,1997,Amphotericin B lipid complex (ABLC),"Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.",India Subcontinent,85.400719,Published,"Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW.",Amphotericin B lipid complex,Dose finding,0,Parasitological,No,vl,
India (IND),26.118589,Unspecified,"222",,,CTRI/2017/05/008656,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",130,,Amphotericin B," A multicenter, open label, randomized, two treatment, parallel design, steady state study to compare the bioavailability of the Test product [Amphotericin B (Liposome for injection) 50 mg/vial, Cipla Ltd., India] with Reference product [AmBisomeÂ® (Amphotericin B) Liposome for injection 50 mg/vial), Gilead life sciences, USA] in adult patients with visceral leishmaniasis.",India Subcontinent,85.400719,Active,"CP Thakur, Rama Prasad Goswami,  Shyam Sundar, Krishna Pandey",Liposomal Amphotericin B,Comparative,0,Unspecified,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"16",http://www.ncbi.nlm.nih.gov/pubmed/21633025,21633025,NCT00381394,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",61,2011,Sitamaquine,"Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M.",Sitamaquine; Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"16",http://www.ncbi.nlm.nih.gov/pubmed/21633025,21633025,NCT00381394,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",61,2011,Amphotericin B deoxycholate,"Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.",India Subcontinent,85.400719,Published,"Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M.",Sitamaquine; Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"29",http://www.ncbi.nlm.nih.gov/pubmed/11127251,11127250,-9,Patna Medical College Hospital,150,2000,Sodium stibogluconate,"A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.",India Subcontinent,85.159811,Published,"Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"38",http://www.ncbi.nlm.nih.gov/pubmed/17682989,17682989,NCT00310506,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",1485,2007,Amphotericin B deoxycholate,Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.,India Subcontinent,85.400719,Published,"Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.",Amphotericin B deoxycholate,Dose finding,0,Parasitological,No,vl,
India (IND),25.620021,Spleen,"41",http://www.ncbi.nlm.nih.gov/pubmed/8707362,8707361,-9,Patna Medical College Hospital,288,1996,Amphotericin B deoxycholate,Comparison of regimens of amphotericin B deoxycholate in kala-azar.,India Subcontinent,85.159811,Published,"Thakur CP, Sinha GP, Pandey AK.",Amphotericin B deoxycholate,Dose finding,0,Parasitological,No,vl,
India (IND),25.274455,Spleen/bone,"61",http://www.ncbi.nlm.nih.gov/pubmed/11049799,11049798,-9,"Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India.",320,2000,Sodium stibogluconate,Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.,India Subcontinent,82.997337,Published,"Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW.",Sodium stibogluconate,Single Group,1,Parasitological,Unspecified,vl,
India (IND),25.599832,,"243",,,NCT03636659; CTRI/2018/04/013350,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",140,,Liposomal Amphotericin B (L-AmB),Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition,India Subcontinent,85.195326,Completed,"Nagesh Meda, Sajid Mohd, Subhra Lahiri, Krishna Pandey, Shyam Sunda, Dinesh Mondal","",Comparative,1,Serological,No,vl,Bangladesh
India (IND),25.59971,,"235",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,"Rajendra Memorial Research Institute of Medical Sciences, Patna",1761,2018,Miltefosine,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.19769,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.59971,,"235",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,"Rajendra Memorial Research Institute of Medical Sciences, Patna",1761,2018,Liposomal Amphotericin B (L-AmB),"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.19769,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.59971,,"235",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,"Rajendra Memorial Research Institute of Medical Sciences, Patna",1761,2018,Paromomycin,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.19769,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.793202,,"226",https://www.ncbi.nlm.nih.gov/pubmed/27645786,27645786,-9,District hospital in Samastipur District,646,2016,Miltefosine,"Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India",India Subcontinent,85.814608,Published,"Krishna Pandey, Vidyanand Ravidas, Niyamat A. Siddiqui, Sanjay K. Sinha, Rakesh B. Verma, Tripurari P. Singh, A. C. Dhariwal, R. K. Das Gupta, and Pradeep Das","",Single Group,1,Parasitological,No,vl,
Bangladesh (BGD),24.6333,,"252",https://pubmed.ncbi.nlm.nih.gov/29554244/,29554244,NCT03311607,"MSF leishmaniasis clinic, Fulbaria upazila, Mymensingh district, Bangladesh",280,2018,Liposomal Amphotericin B (L-AmB), Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post-Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh,India Subcontinent,90.2667,Published,"Margriet den Boer, Asish Kumar Das, Fatima Akhter, Sakib Burza, V Ramesh, Be-Nazir Ahmed, Eduard E Zijlstra, Koert Ritmeijer","",Single-arm trial,0,Mixed,Unspecified,pkdl,
Sudan (SDN),13.511629,bone/lymph,"206",,,NCT01980199,"El Hassan Centre for Tropical Medicine, Doka,Sudan",66,,Fexinidazole,Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan,Eastern Africa,35.740262,Terminated,"Ahmed M Musa, E. AG Khalil, Nathalie Strub-Wourgaft, Séverine Blesson",Fexinidazole,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.602357,Spleen,"135",http://www.ncbi.nlm.nih.gov/pubmed/17202605,17202605,-9,Nalanda Medical College,64,2006,Miltefosine,Miltefosine in children with visceral leishmaniasis.,India Subcontinent,85.197018,Published,"Singh UK, Prasad R, Kumar R, Jaiswal BP.",Miltefosine,Single Group,0,Parasitological,No,vl,
Uganda (UGA),1.233932,,"232",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Uganda - Site Unknown,3126,2017,Sodium stibogluconate,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,32.413367,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Kenya, Sudan, Ethiopia"
Uganda (UGA),1.233932,,"232",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/,,-9,Uganda - Site Unknown,3126,2017,Paromomycin,Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme,Eastern Africa,32.413367,Published,"Robert Kimutai, Ahmed M. Musa, Simon Njoroge, Raymond Omollo, Fabiana Alves, Asrat Hailu, Eltahir A. G. Khalil, Ermias Diro, Peninah Soipei, Brima Musa, Khalid Salman, Koert Ritmeijer, Francois Chappuis, Juma Rashid, Rezika Mohammed, Asfaw Jameneh, Eyasu Makonnen, Joseph Olobo, Lawrence Okello, Patrick Sagaki, Nathalie Strub, Sally Ellis, Jorge Alvar, Manica Balasegaram, Emilie Alirol, and Monique Wasunna","",Single Group,1,Mixed,Yes,vl,"Kenya, Sudan, Ethiopia"
India (IND),26.118589,Spleen/bone,"114",http://www.ncbi.nlm.nih.gov/pubmed/11127252,11127251,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",120,2000,Sodium stibogluconate,Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.,India Subcontinent,85.400719,Published,"Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P.",Sodium stibogluconate; Paromomycin,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"114",http://www.ncbi.nlm.nih.gov/pubmed/11127252,11127251,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",120,2000,Paromomycin,Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.,India Subcontinent,85.400719,Published,"Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P.",Sodium stibogluconate; Paromomycin,Dose finding,0,Parasitological,Unspecified,vl,
Kenya (KEN),0.4855854,Spleen,"113",http://www.ncbi.nlm.nih.gov/pubmed/2167523,2167522,-9,Kabarnet District Hospital,56,1990,Sodium stibogluconate,Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.,Eastern Africa,35.74316,Published,"Chunge CN, Owate J, Pamba HO, Donno L.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
Kenya (KEN),0.4855854,Spleen,"113",http://www.ncbi.nlm.nih.gov/pubmed/2167523,2167522,-9,Kabarnet District Hospital,56,1990,Paromomycin,Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.,Eastern Africa,35.74316,Published,"Chunge CN, Owate J, Pamba HO, Donno L.",Sodium stibogluconate; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
Kenya (KEN),-1.313005,Spleen/bone,"125",http://www.ncbi.nlm.nih.gov/pubmed/9615495,9615494,-9,"Kenya Medical Research institute, Nairobi, Kenya",87,1998,Liposomal Amphotericin B (L-AmB),Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.,Eastern Africa,36.803282,Published,"Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,Unspecified,vl,"Brazil, India"
Nepal (NPL),26.80877,Bone,"30",http://www.ncbi.nlm.nih.gov/pubmed/9740293,9740292,-9,"B. P. Koirala Institute of Health Sciences (BPKIHS),",54,1998,Sodium stibogluconate,A thirty-day course of sodium stibogluconate for treatment of Kala-azar in Nepal.,India Subcontinent,87.262131,Published,"Karki P, Koirala S, Parija SC, Hansdak SG, Das ML.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),25.612677,,"251",https://pubmed.ncbi.nlm.nih.gov/9425363/,9425363,,"Kala-azar Research Centre, Patna, India",22,1997,Sodium stibogluconate,Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis,India Subcontinent,85.158875,Published,"CP Thakur, S Narain, N Kumar, SM Hassan, DK Jha, A Kumar ","",RCT,0,Mixed,No,pkdl,
India (IND),25.612677,,"251",https://pubmed.ncbi.nlm.nih.gov/9425363/,9425363,,"Kala-azar Research Centre, Patna, India",22,1997,Amphotericin B deoxycholate,Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis,India Subcontinent,85.158875,Published,"CP Thakur, S Narain, N Kumar, SM Hassan, DK Jha, A Kumar ","",RCT,0,Mixed,No,pkdl,
Tunisia,34.019934,Bone,"23",http://www.ncbi.nlm.nih.gov/pubmed/8708370,8708370,-9,Tunisia - Site unknown,10,1996,Liposomal Amphotericin B (L-AmB),Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).,Mediterranean,9.330489,Published,"Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN.",Amphotericin B,Single Group,1,Parasitological,Yes,vl,"Portugal, France"
India (IND),25.613897,Spleen/bone,"25",http://www.ncbi.nlm.nih.gov/pubmed/15035723,15035723,-9,"Balaji Uthan Sansthan, Patna, India",120,2004,Sodium stibogluconate,"A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis.",India Subcontinent,85.139591,Published,"Thakur CP, Narayan S.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,No,vl,
India (IND),25.613897,Spleen/bone,"25",http://www.ncbi.nlm.nih.gov/pubmed/15035723,15035723,-9,"Balaji Uthan Sansthan, Patna, India",120,2004,Amphotericin B deoxycholate,"A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis.",India Subcontinent,85.139591,Published,"Thakur CP, Narayan S.",Amphotericin B; Sodium stibogluconate,Comparative,0,Parasitological,No,vl,
Brazil (BRA),-16.718505,,"200",,,NCT00378495,"Universidade Estadual de Montes Claros, Brazil",80,,Miltefosine,Miltefosine for Brazilian Visceral Leishmaniasis,South America,-43.879748,Terminated,Reynaldo Dietze,Miltefosine,Single Group,0,Parasitological,Unspecified,vl,
Kenya (KEN),-1.5234907,Spleen,"46",http://www.ncbi.nlm.nih.gov/pubmed/6130247,6130246,-9,Machakos Provincial Hospital,54,1983,Sodium stibogluconate,Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya.,Eastern Africa,37.264193,Published,"Anabwani GM, Ngira JA, Dimiti G, Bryceson AD.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
Brazil (BRA),-10.893701,Bone,"201",https://www.ncbi.nlm.nih.gov/pubmed/28662035,28662035,NCT01310739,"Hospital Universitário da Universidade Federal de Sergipe,Brazil",378,2017,Meglumine antimoniate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-37.066722,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-10.893701,Bone,"201",https://www.ncbi.nlm.nih.gov/pubmed/28662035,28662035,NCT01310739,"Hospital Universitário da Universidade Federal de Sergipe,Brazil",378,2017,Amphotericin B deoxycholate,"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-37.066722,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
Brazil (BRA),-10.893701,Bone,"201",https://www.ncbi.nlm.nih.gov/pubmed/28662035,28662035,NCT01310739,"Hospital Universitário da Universidade Federal de Sergipe,Brazil",378,2017,Liposomal Amphotericin B (L-AmB),"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open-label trial.",South America,-37.066722,Published,"Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.",Meglumine antimoniate; Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Mixed,No,vl,
India (IND),26.118589,Spleen,"54",http://www.ncbi.nlm.nih.gov/pubmed/22573857,22573856,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",567,2012,Miltefosine,Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.,India Subcontinent,85.400719,Published,"Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J.",Miltefosine,Single Group,0,Parasitological,No,vl,
Brazil (BRA),-20.277539,Spleen/bone,"109",http://www.ncbi.nlm.nih.gov/pubmed/8110957,8110956,-1,"Tropical Medicine Unit, Federal University of Espirito Santo",20,1993,Amphotericin B colloidal dispersion (ABCD),Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).,South America,-40.304396,Published,"Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, Luz KG, Suassuna FA, Marinho LA, Ksionski G.",Amphotericin B dispersion,Dose finding,0,Parasitological,Unspecified,vl,
United Kingdom,54.925671,Bone,"93",http://www.ncbi.nlm.nih.gov/pubmed/8783691,8783690,-9,United Kingdom - site unknown,88,1996,Liposomal Amphotericin B (L-AmB),Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).,Europe,-2.840688,Published,"Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,"Italy, Brazil"
India (IND),25.599832,Unspecified,"223",,,CTRI/2017/05/008656,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",130,,Amphotericin B," A multicenter, open label, randomized, two treatment, parallel design, steady state study to compare the bioavailability of the Test product [Amphotericin B (Liposome for injection) 50 mg/vial, Cipla Ltd., India] with Reference product [AmBisomeÂ® (Amphotericin B) Liposome for injection 50 mg/vial), Gilead life sciences, USA] in adult patients with visceral leishmaniasis.",India Subcontinent,85.195326,Active,"CP Thakur, Rama Prasad Goswami,  Shyam Sundar, Krishna Pandey",Liposomal Amphotericin B,Comparative,0,Unspecified,Unspecified,vl,
India (IND),25.620021,Spleen,"7",http://www.ncbi.nlm.nih.gov/pubmed/7886778,7886778,-9,Patna Medical College Hospital,22,1994,Amphotericin B - formulation unknown,Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar.,India Subcontinent,85.159811,Published,Thakur CP.,Amphotericin B deoxycholate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen,"7",http://www.ncbi.nlm.nih.gov/pubmed/7886778,7886778,-9,Patna Medical College Hospital,22,1994,Amphotericin B deoxycholate,Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar.,India Subcontinent,85.159811,Published,Thakur CP.,Amphotericin B deoxycholate,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.352372,Spleen/bone/serological,"161",http://www.ncbi.nlm.nih.gov/pubmed/16730363,16730363,-1,"District Sadar Hospital, Bihar, India",64,2006,Liposomal Amphotericin B (L-AmB),Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.,Eastern Africa,85.31256,Published,"Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, ParreÃ±o F, Pandey K.",Liposomal Amphotericin B,Single Group,0,Mixed,Yes,vl,
India (IND),25.691372,,"234",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Hajipur District Hospitla (Vaishali),1761,2018,Miltefosine,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.209057,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.691372,,"234",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Hajipur District Hospitla (Vaishali),1761,2018,Liposomal Amphotericin B (L-AmB),"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.209057,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.691372,,"234",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Hajipur District Hospitla (Vaishali),1761,2018,Paromomycin,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.209057,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
Italy (ITA),41.067621,Bone,"91",http://www.ncbi.nlm.nih.gov/pubmed/8783691,8783690,-9,Seconda università degli studi di napoli,88,1996,Liposomal Amphotericin B (L-AmB),Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).,Mediterranean,14.329145,Published,"Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,"Brazil, United Kingdom"
Saudi Arabia (SAU),16.922341,Unknown,"142",http://www.ncbi.nlm.nih.gov/pubmed/3014838,3014837,-9,"King Fahd Central Hospital, Gizan",16,1986,Allopurinol,A comparative study of allopurinol and pentostam in the treatment of visceral leishmaniasis.,Central Asia,42.733659,Published,"Tobaigy M, Mejer J, Peitersen B, Ansari M, Poll P.",Sodium stibogluconate; Allopurinol,Comparative,0,Unspecified,Unspecified,vl,
Saudi Arabia (SAU),16.922341,Unknown,"142",http://www.ncbi.nlm.nih.gov/pubmed/3014838,3014837,-9,"King Fahd Central Hospital, Gizan",16,1986,Sodium stibogluconate,A comparative study of allopurinol and pentostam in the treatment of visceral leishmaniasis.,Central Asia,42.733659,Published,"Tobaigy M, Mejer J, Peitersen B, Ansari M, Poll P.",Sodium stibogluconate; Allopurinol,Comparative,0,Unspecified,Unspecified,vl,
Sudan (SDN),14.039853,Bone,"166",http://www.ncbi.nlm.nih.gov/pubmed/19766208,19766208,-9,Gadarif Hospital,42,2009,Sodium stibogluconate,Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan.,Eastern Africa,35.387,Published,"Adam GK, Abdulla MA, Ahmed AA, Adam I.",Sodium stibogluconate,Single Group,0,Parasitological,No,vl,
Brazil (BRA),-5.7972951,Bone,"112",http://www.ncbi.nlm.nih.gov/pubmed/7660447,7660446,-9,Hospital Giselda Trigueiro,10,1995,Amphotericin B colloidal dispersion (ABCD),Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.,South America,-35.228215,Published,"Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, Fonschiffrey G, Ksionski G, Dember J.",Amphotericin B dispersion,Single Group,1,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"70",http://www.ncbi.nlm.nih.gov/pubmed/17582069,17582069, NCT00216348,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",667,2007,Amphotericin B - formulation unknown,Injectable paromomycin for Visceral leishmaniasis in India.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.",Amphotericin B; Paromomycin,Comparative,1,Parasitological,No,vl,
India (IND),26.118589,Spleen/bone,"70",http://www.ncbi.nlm.nih.gov/pubmed/17582069,17582069, NCT00216348,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",667,2007,Paromomycin,Injectable paromomycin for Visceral leishmaniasis in India.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.",Amphotericin B; Paromomycin,Comparative,1,Parasitological,No,vl,
India (IND),25.352372,,"225",https://www.ncbi.nlm.nih.gov/pubmed/27645786,27645786,-9,"District Sadar Hospital, Bihar, India",646,2016,Miltefosine,"Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India",India Subcontinent,85.31256,Published,"Krishna Pandey, Vidyanand Ravidas, Niyamat A. Siddiqui, Sanjay K. Sinha, Rakesh B. Verma, Tripurari P. Singh, A. C. Dhariwal, R. K. Das Gupta, and Pradeep Das","",Single Group,1,Parasitological,No,vl,
Italy (ITA),44.391586,Unknown,"132",http://www.ncbi.nlm.nih.gov/pubmed/8758093,8758092,-9,G. Gaslini Children’s Hospital,29,1996,Liposomal Amphotericin B (L-AmB),Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis.,Mediterranean,8.9861786,Published,"Castagnola E, Davidson RN, Fiore P, Tasso L, Rossi G, Mangraviti S, Di Martino L, Scotti S, Cascio A, Pempinello R, Gradoni L, Giacchino R.",Liposomal Amphotericin B,Dose finding,0,Unspecified,No,vl,
India (IND),25.797004,,"237",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Vaishali,1761,2018,Miltefosine,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.358865,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.797004,,"237",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Vaishali,1761,2018,Liposomal Amphotericin B (L-AmB),"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.358865,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.797004,,"237",https://www.ncbi.nlm.nih.gov/pubmed/30346949,30346949,CTRI/2012/08/002891,Primary Health Clinic in Vaishali,1761,2018,Paromomycin,"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India",India Subcontinent,85.358865,Published,"Vishal Goyal, Raman Mahajan, Krishna Pandey, Shambhu Nath Singh, Ravi Shankar Singh, Nathalie Strub-Wourgaft, Fabiana Alves, Vidya Nand Rabi Das, Roshan Kamal Topno, Bhawna Sharma, Manica Balasegaram, Caryn Bern, Allen Hightower, Suman Rijal, Sally Ellis, Temmy Sunyoto, Sakib Burza, Nines Lima, Pradeep Das, Jorge Alvar","",Non-comparative multi-arm,1,Mixed,No,vl,
India (IND),25.6141,Spleen,"149",http://www.ncbi.nlm.nih.gov/pubmed/11229247,11229246,-9,"Kala-azar Research Centre of Balaji Utthan Sansthan, Patna.",130,1998,Amphotericin B deoxycholate,A randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar.,India Subcontinent,85.14227,Published,"Thakur CP, Kumar P, Kumar N, Singh GN, Singh AK, Narain S.",Amphotericin B deoxycholate,Dose finding,0,Parasitological,No,vl,
Sudan (SDN),13.583108,Spleen/bone/lymph,"65",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Um el Kheir Treatment Center, Gedaref State, Sudan",270,2010,Sodium stibogluconate,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,35.087274,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Kenya"
Sudan (SDN),13.583108,Spleen/bone/lymph,"65",http://www.ncbi.nlm.nih.gov/pubmed/21049060,21049060,NCT00255568,"Um el Kheir Treatment Center, Gedaref State, Sudan",270,2010,Paromomycin,"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.",Eastern Africa,35.087274,Published,"Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Ethiopia, Kenya"
Brazil (BRA),-20.277548,Spleen,"81",http://www.ncbi.nlm.nih.gov/pubmed/11791958,11791957,-9,"Biomedical Center of the Federal University of Espirito Santo, Vitoria, Brazil",22,2001,Sitamaquine,"Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.",South America,-40.305624,Published,"Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M.",Sitamaquine,Dose finding,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"86",http://www.ncbi.nlm.nih.gov/pubmed/2840173,2840172,-9,Patna Medical College Hospital,371,1988,Sodium stibogluconate,Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"100",http://www.ncbi.nlm.nih.gov/pubmed/20147717,20147717,NCT00628720,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",412,2010,Amphotericin B deoxycholate,Single-dose liposomal amphotericin B for visceral leishmaniasis in India.,India Subcontinent,85.400719,Published,"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.",Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"100",http://www.ncbi.nlm.nih.gov/pubmed/20147717,20147717,NCT00628720,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",412,2010,Liposomal Amphotericin B (L-AmB),Single-dose liposomal amphotericin B for visceral leishmaniasis in India.,India Subcontinent,85.400719,Published,"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.",Amphotericin B deoxycholate; Liposomal Amphotericin B,Comparative,0,Parasitological,No,vl,
India (IND),25.612677,,"255",https://pubmed.ncbi.nlm.nih.gov/27781268/,27781268,CTRI/2016/04/006898,"Rajendra Memorial Research Institute of Medical Sciences, Patna, India",30,2017,Miltefosine,Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. ,India Subcontinent,85.158875,Published,"K Pandey, B Pal, VNR Das, K Murti, CS Lal, N Verma, S Bimal, V Ali, RB Verma, RK Topno, NA Siddiqi, P Das","",RCT,0,Mixed,No,pkdl,
India (IND),25.612677,,"255",https://pubmed.ncbi.nlm.nih.gov/27781268/,27781268,CTRI/2016/04/006898,"Rajendra Memorial Research Institute of Medical Sciences, Patna, India",30,2017,Paromomycin,Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. ,India Subcontinent,85.158875,Published,"K Pandey, B Pal, VNR Das, K Murti, CS Lal, N Verma, S Bimal, V Ali, RB Verma, RK Topno, NA Siddiqi, P Das","",RCT,0,Mixed,No,pkdl,
India (IND),25.352372,Bone,"158",https://www.ncbi.nlm.nih.gov/pubmed/9707884,9707883,-9,"District Sadar Hospital, Bihar, India",20,1998,Fluconazole,Fluconazole in visceral leishmaniasis.,India Subcontinent,85.31256,Published,Jha BB.,Fluconazole,Single Group,0,Parasitological,Unspecified,vl,
India (IND),25.613897,Spleen/bone,"77",http://www.ncbi.nlm.nih.gov/pubmed/12135285,12135284,-9,"Balaji Uthan Sansthan, Patna, India",84,2002,Liposomal Amphotericin B (L-AmB),Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.,India Subcontinent,85.139591,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,
India (IND),26.131728,Bone,"120",http://www.ncbi.nlm.nih.gov/pubmed/1359323,1359322,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",120,1992,Amphotericin B - formulation unknown,Amphotericin versus pentamidine in antimony-unresponsive kala-azar.,India Subcontinent,85.896955,Published,"Mishra M, Biswas UK, Jha DN, Khan AB.",Amphotericin B; Pentamidine; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
India (IND),26.131728,Bone,"120",http://www.ncbi.nlm.nih.gov/pubmed/1359323,1359322,-9,"Darbhanga Medical College, Darbhanga, Bihar-846003, India",120,1992,Paromomycin,Amphotericin versus pentamidine in antimony-unresponsive kala-azar.,India Subcontinent,85.896955,Published,"Mishra M, Biswas UK, Jha DN, Khan AB.",Amphotericin B; Pentamidine; Paromomycin,Comparative,0,Parasitological,Unspecified,vl,
Italy (ITA),44.391586,Bone,"139",http://www.ncbi.nlm.nih.gov/pubmed/9290616,9290615,-9,G. Gaslini Children’s Hospital,106,1997,Liposomal Amphotericin B (L-AmB),Treatment of visceral leishmaniasis in children with liposomal amphotericin B.,Mediterranean,8.9861786,Published,"di Martino L, Davidson RN, Giacchino R, Scotti S, Raimondi F, Castagnola E, Tasso L, Cascio A, Gradoni L, Gramiccia M, Pettoello-Mantovani M, Bryceson AD.",Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Kenya (KEN),-1.313005,Spleen,"177",http://www.ncbi.nlm.nih.gov/pubmed/7835264,7835263,-9,Kenya Medical Research institute,7,1994,Ketoconazole,The efficacy and safety of ketoconazole in visceral leishmaniasis.,Eastern Africa,36.803282,Published,"Rashid JR, Wasunna KM, Gachihi GS, Nyakundi PM, Mbugua J, Kirigi G.",Ketoconazole,Single Group,0,Parasitological,No,vl,
Ethiopia (ETH),6.0284459,Spleen/bone/lymph,"105",http://www.ncbi.nlm.nih.gov/pubmed/22724031,22724031,NCT00255569,"Arba Minch Hospital, SNNPR State, Ethiopia",972,2012,Sodium stibogluconate,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,37.550195,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Sudan, Kenya"
Ethiopia (ETH),6.0284459,Spleen/bone/lymph,"105",http://www.ncbi.nlm.nih.gov/pubmed/22724031,22724031,NCT00255569,"Arba Minch Hospital, SNNPR State, Ethiopia",972,2012,Paromomycin,Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.,Eastern Africa,37.550195,Published,"Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, et al.",Sodium stibogluconate; Paromomycin,Comparative,1,Parasitological,Yes,vl,"Uganda, Sudan, Kenya"
Nepal (NPL),26.80877,Spleen/bone,"122",http://www.ncbi.nlm.nih.gov/pubmed/19726066,19726065,-9,"B. P. Koirala Institute of Health Sciences (BPKIHS),",198,2010,Sodium stibogluconate,Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.,India Subcontinent,87.262131,Published,"Rijal S, Bhandari S, Koirala S, Singh R, Khanal B, Loutan L, Dujardin JC, Boelaert M, Chappuis F.",Sodium stibogluconate,Single Group,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen,"110",http://www.ncbi.nlm.nih.gov/pubmed/11520837,11520836,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",91,2001,Liposomal Amphotericin B (L-AmB),Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.,India Subcontinent,85.400719,Published,"Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW.",Liposomal Amphotericin B,Dose finding,0,Parasitological,No,vl,
Uganda (UGA),1.954237,,"182",https://www.ncbi.nlm.nih.gov/pubmed/30188979,30188979,NCT02431144,"Amudat Hospital, Uganda",30,2018,Miltefosine,"Pharmacokinetics, safety and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial",Eastern Africa,34.945197,Published,Rashid Juma,Miltefosine,Single Group,1,Parasitological,No,vl,Kenya
India (IND),25.599832,,"187",,,CTRI/2009/091/000058,"Rajendra Memorial Research Institute of Medical Sciences , Patna, Bihar",,,Liposomal Amphotericin B (L-AmB),"A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul (Amphotericin B Emulsion) As Compared To AmBisome In Patients Of Visceral Leishmaniasis (Kala Azar)",India Subcontinent,85.195326,Completed,Krishna Pandey ,Liposomal Amphotericin B,Comparative,1,Mixed,Unspecified,vl,
Ethiopia (ETH),6.0284459,Spleen/bone/lymph,"88",http://www.ncbi.nlm.nih.gov/pubmed/24454971,24454971, NCT00832209,"Arba Minch Hospital, SNNPR State, Ethiopia",124,2014,Liposomal Amphotericin B (L-AmB),Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.,Eastern Africa,37.550195,Published,"Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,Sudan
Greece (GRC),37.984785,Bone,"140",http://www.ncbi.nlm.nih.gov/pubmed/12594636,12594635,-9,"Aghia Sophia Children’s Hospital,Greece",123,2003,Meglumine antimoniate,Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.,Mediterranean,23.766712,Published,"Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G.",Liposomal Amphotericin B,Single Group,0,Parasitological,No,vl,
Greece (GRC),37.984785,Bone,"140",http://www.ncbi.nlm.nih.gov/pubmed/12594636,12594635,-9,"Aghia Sophia Children’s Hospital,Greece",123,2003,Liposomal Amphotericin B (L-AmB),Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.,Mediterranean,23.766712,Published,"Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G.",Liposomal Amphotericin B,Single Group,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"42",http://www.ncbi.nlm.nih.gov/pubmed/6322907,6322906,-9,Patna Medical College Hospital,126,1984,Sodium stibogluconate,Comparison of regimens of treatment with sodium stibogluconate in kala-azar.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RS, Dhawan PS, Achari V.",Sodium stibogluconate,Dose finding,0,Parasitological,Unspecified,vl,
India (IND),26.118589,Spleen/bone,"74",http://www.ncbi.nlm.nih.gov/pubmed/12135285,12135284,-9,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",84,2002,Liposomal Amphotericin B (L-AmB),Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.,India Subcontinent,85.400719,Published,"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R.",Liposomal Amphotericin B,Dose finding,1,Parasitological,No,vl,
India (IND),26.118589,Spleen,"94",http://www.ncbi.nlm.nih.gov/pubmed/19663598,19663598,NCT00629032,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",329,2009,Paromomycin sulphate,Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.,India Subcontinent,85.400719,Published,"Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J.",Paromomycin,Dose finding,0,Parasitological,No,vl,
India (IND),26.118589,Spleen,"94",http://www.ncbi.nlm.nih.gov/pubmed/19663598,19663598,NCT00629032,"Kala-azar Medical Research Center, Rambag Road , Muzaffarpur,  Bihar -842001",329,2009,Paromomycin,Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.,India Subcontinent,85.400719,Published,"Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J.",Paromomycin,Dose finding,0,Parasitological,No,vl,
India (IND),25.620021,Spleen/bone,"169",http://www.ncbi.nlm.nih.gov/pubmed/1323161,1323160,-9,Patna Medical College Hospital,40,1992,"",Observations on the effect of verapamil with sodium stibogluconate in kala azar.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M.",Sodium stibogluconate; Verapamil; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"169",http://www.ncbi.nlm.nih.gov/pubmed/1323161,1323160,-9,Patna Medical College Hospital,40,1992,Pentamidine,Observations on the effect of verapamil with sodium stibogluconate in kala azar.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M.",Sodium stibogluconate; Verapamil; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"169",http://www.ncbi.nlm.nih.gov/pubmed/1323161,1323160,-9,Patna Medical College Hospital,40,1992,Sodium stibogluconate,Observations on the effect of verapamil with sodium stibogluconate in kala azar.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M.",Sodium stibogluconate; Verapamil; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
India (IND),25.620021,Spleen/bone,"169",http://www.ncbi.nlm.nih.gov/pubmed/1323161,1323160,-9,Patna Medical College Hospital,40,1992,verapamil,Observations on the effect of verapamil with sodium stibogluconate in kala azar.,India Subcontinent,85.159811,Published,"Thakur CP, Kumar M.",Sodium stibogluconate; Verapamil; Pentamidine,Comparative,0,Parasitological,Unspecified,vl,
